MedKoo product information:

 Carboplatin

carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

History

Carboplatin was discovered and developed at the Institute of Cancer Research in London. Bristol-Myers Squibb gained Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. Starting in October 2004, generic versions of the drug became available. From: http://en.wikipedia.org/wiki/Carboplatin.

DRUG DESCRIPTION

PARAPLATIN® (carboplatin aqueous solution) INJECTION is supplied as a sterile, pyrogen-free, 10 mg/mL aqueous solution of carboplatin. Carboplatin is a platinum coordination compound. Carboplatin is a crystalline powder with the molecular formula of C6H12N2O4Pt and a molecular weight of 371.25. It is soluble in water at a rate of approximately 14 mg/mL, and the pH of a 1% solution is 5 to 7. It is virtually insoluble in ethanol, acetone, and dimethylacetamide.

CLINICAL PHARMACOLOGY

Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.

In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 mg/m2 to 500 mg/m2 of carboplatin. The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (n=6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (n=6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The Cmax values and areas under the plasma concentration versus time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300 mg/m2 to 500 mg/m2).

Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.

The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs.

 1: Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs

in the clinic and in clinical trials. Dalton Trans. 2010 Jun 30. [Epub ahead of print] PubMed PMID: 20593091.

2: Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Mol Cancer Ther. 2010 Jul;9(7):1956-67. Epub 2010 Jun 22. PubMed PMID: 20571069.

3: Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR. Advances in platinum chemotherapeutics. Chemistry. 2010 Jun 25;16(24):7064-77. PubMed PMID: 20533453.

4: Xie M, Liu W, Lou L, Chen X, Ye Q, Yu Y, Chang Q, Hou S. Unusual dimeric chemical structure for a carboplatin analogue as a potential anticancer complex.

Inorg Chem. 2010 Jul 5;49(13):5792-4. PubMed PMID: 20515022.

5: Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S, Gemma A. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2010 May 19. [Epub ahead of print] PubMed PMID: 20493578.

6: Ang WH, Myint M, Lippard SJ. Transcription inhibition by platinum-DNA cross-links in live mammalian cells. J Am Chem Soc. 2010 Jun 2;132(21):7429-35. PubMed PMID: 20443565; PubMed Central PMCID: PMC2877768.

7: Hah SS, Henderson PT, Turteltaub KW. Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2448-51. Epub 2010 Mar 7. PubMed PMID: 20335033.

8: Emmanouilides C, Yermetaki T, Serpanou A, Sapountzi E, Mantziari P, Titopoulos I, Filippou D. Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer. Hematol Oncol Stem Cell Ther. 2010;3(1):34-8. PubMed PMID: 20231811.

9: Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010 Apr 7;132(13):4678-84. PubMed PMID: 20225865.

10: Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ. PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics. 2010 Apr;20(4):269-73. PubMed PMID: 20216476.

11: Groessl M, Tsybin YO, Hartinger CG, Keppler BK, Dyson PJ. Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. J Biol Inorg Chem. 2010 Jun;15(5):677-88. Epub 2010 Mar 7. PubMed PMID: 20213306.

12: Pölcher M, Eckhardt M, Coch C, Wolfgarten M, Kübler K, Hartmann G, Kuhn W, Rudlowski C. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol. 2010 May;66(1):203-7. Epub 2010 Mar 5. PubMed PMID: 20204367.

13: Olszewski U, Hamilton G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem. 2010 May 1;10(4):293-301. PubMed PMID: 20187870.

14: Zhang J, Wang L, Xing Z, Liu D, Sun J, Li X, Zhang Y. Status of bi- and multi-nuclear platinum anticancer drug development. Anticancer Agents Med Chem. 2010 May 1;10(4):272-82. PubMed PMID: 20184553.

15: McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer. 2010 Apr 15;116(8):1859-71. Review. PubMed PMID: 20166210.

16: Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010 Feb;159(4):898-908. Epub 2010 Jan 8. PubMed PMID: 20067471; PubMed Central PMCID: PMC2829215.

17: Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics. 2009 Jan 1;1(4):280-291. PubMed PMID: 20046924; PubMed Central PMCID: PMC2752884.

18: Sanchez-Cano C, Hannon MJ. Novel and emerging approaches for the delivery of

metallo-drugs. Dalton Trans. 2009 Dec 28;(48):10702-11. Epub 2009 Oct 21. Review. PubMed PMID: 20023897.

19: Ikeda S, Takabe K, Suzuki K. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int. 2009 Dec;59(12):863-7. Erratum in: Pathol Int. 2010 Feb;60(2):148. PubMed PMID: 20021611.

20: Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi GY, Li H, Yi J, Wang J. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol. 2010 Apr 15;79(8):1134-40.

Epub 2009 Dec 11. PubMed PMID: 20005210.

21: Chappuy M, Caudron E, Bellanger A, Pradeau D. Determination of platinum traces contamination by graphite furnace atomic absorption spectrometry after preconcentration by cloud point extraction. J Hazard Mater. 2010 Apr 15;176(1-3):207-12. Epub 2009 Nov 6. PubMed PMID: 19962825.

22: Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer. 2010 Aug;69(2):155-164. Epub 2009

Dec 4. PubMed PMID: 19962780.

23: Pirker R, Minar W. Chemotherapy of advanced non-small cell lung cancer. Front Radiat Ther Oncol. 2010;42:157-63. Epub 2009 Nov 24. Review. PubMed PMID: 19955802.

24: Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010 Jan

10;28(2):193-201. Epub 2009 Nov 30. PubMed PMID: 19949019.

25: Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 1;28(1):56-62. Epub 2009 Nov 23. PubMed PMID: 19933908; PubMed Central PMCID: PMC2799233.

26: Zhang J, Liu D, Li Y, Sun J, Wang L, Zang A. Status of non-classical mononuclear platinum anticancer drug development. Mini Rev Med Chem. 2009 Oct;9(11):1357-66. Review. PubMed PMID: 19929810.

27: Ha SW, Kim YJ, Kim W, Lee CS. Antitumor Effects of Camptothecin Combined with Conventional Anticancer Drugs on the Cervical and Uterine Squamous Cell Carcinoma Cell Line SiHa. Korean J Physiol Pharmacol. 2009 Apr;13(2):115-21. Epub 2009 Apr

30. PubMed PMID: 19885006; PubMed Central PMCID: PMC2766704.

28: Nanjwade BK, Singh J, Parikh KA, Manvi FV. Preparation and evaluation of carboplatin biodegradable polymeric nanoparticles. Int J Pharm. 2010 Jan 29;385(1-2):176-80. Epub 2009 Oct 23. PubMed PMID: 19854254.

29: Nowak-Markwitz E. [Pegylated liposomal doxorubicin in ovarian cancer treatment]. Ginekol Pol. 2009 Aug;80(8):615-9. Review. Polish. PubMed PMID: 19824461.

30: Ndinguri MW, Solipuram R, Gambrell RP, Aggarwal S, Hammer RP. Peptide Targeting of Platinum Anti-Cancer Drugs. Bioconjug Chem. 2009 Sep 23. [Epub ahead of print] PubMed PMID: 19775102; PubMed Central PMCID: PMC2891414.

31: Di Pasqua AJ, Wallner S, Kerwood DJ, Dabrowiak JC. Adsorption of the Pt(II) anticancer drug carboplatin by mesoporous silica. Chem Biodivers. 2009 Sep;6(9):1343-9. PubMed PMID: 19774597.

32: Ningaraj NS, Sankpal UT, Khaitan D, Meister EA, Vats TS. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. Cancer Biol Ther. 2009 Oct;8(20):1924-33. Epub 2009 Oct 12. PubMed PMID: 19738431.

33: Guiu S, Guiu B, Feutray S, Chauffert B. Direct intratumoral chemotherapy with carboplatin and epinephrine in a recurrent cervical chordoma: case report. Neurosurgery. 2009 Sep;65(3):E629-30; discussion E630. PubMed PMID: 19687674.

34: Jacobs S, McCully CL, Murphy RF, Bacher J, Balis FM, Fox E. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol. 2010 Apr;65(5):817-24. Epub 2009 Aug 7. PubMed PMID: 19662415.

35: Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Imamura F, Minamikawa K, Takano T, Kobayashi H. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer. 2010 Jun;68(3):472-7. Epub 2009 Aug 5. PubMed PMID: 19660825.

36: Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an antibody targeting TRAIL-R1, in combination with

paclitaxel and carboplatin in patients with advanced solid malignancies: results

of a phase I and pharmacokinetic study. J Clin Oncol. 2009 Sep 10;27(26):4413-21. Epub 2009 Aug 3. PubMed PMID: 19652058.

37: Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer. 2009 Jul;10(4):262-72. Review. PubMed PMID: 19632946.

38: Owonikoko TK, Sun SY, Ramalingam SS. The role of cetuximab in the management

of non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul;10(4):230-8. Review. PubMed PMID: 19632939.

39: Ide Y, Nakahara T, Nasu M, Tominaga N, Ohyama A, Tachibana T, Yasuda M. Establishment and characterization of the NEYS cell line derived from carcinosarcoma of human ovary with special reference to the susceptibility test of anticancer drugs. Hum Cell. 2009 Aug;22(3):72-80. Epub 2009 Jun 23. PubMed PMID: 19624308.

40: Provost K, Bouvet-Muller D, Crauste-Manciet S, Moscovici J, Olivi L, Vlaic G, Michalowicz A. EXAFS structural study of platinum-based anticancer drugs degradation in presence of sulfur nucleophilic species. Biochimie. 2009 Oct;91(10):1301-6. Epub 2009 Jul 14. PubMed PMID: 19607872.

41: Yano Y, Kodawara T, Hongo H, Yano I, Kishi Y, Takahashi J, Inui K. Population analysis of myelosuppression profiles using routine clinical data after the ICE (ifosfamide/carboplatin/etoposide) regimen for malignant gliomas. J Pharm Sci. 2009 Nov;98(11):4402-12. PubMed PMID: 19593785.

42: Han SJ, Ahn TK, Choi HS, Shin JN, Piya S, Kim TH. TRAIL-induced cell death and caspase-8 activation are inhibited by cisplatin but not carboplatin. J Gynecol Oncol. 2009 Jun;20(2):113-6. Epub 2009 Jun 29. PubMed PMID: 19590723; PubMed Central PMCID: PMC2704992.

43: Yajima T, Ochiai H, Uchiyama T, Takano N, Shibahara T, Azuma T. Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int J Oncol. 2009 Aug;35(2):273-80. PubMed PMID: 19578740.

44: Rolff J, Dorn C, Merk J, Fichtner I. Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers. J Oncol. 2009;2009:814140. Epub 2009 Jun 14. PubMed PMID: 19547715; PubMed Central PMCID: PMC2696640.

45: Koshiba H, Hosokawa K, Mori T, Kubo A, Watanabe A, Honjo H. Intravenous paclitaxel is specifically retained in human gynecologic carcinoma tissues in vivo. Int J Gynecol Cancer. 2009 May;19(4):484-8. PubMed PMID: 19509540.

46: Fewell JG, Matar MM, Rice JS, Brunhoeber E, Slobodkin G, Pence C, Worker M, Lewis DH, Anwer K. Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med. 2009 Aug;11(8):718-28. PubMed PMID: 19507172.

47: Xing R, Wang X, Zhang C, Zhang Y, Wang Q, Yang Z, Guo Z. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin. J Inorg Biochem. 2009 Jul;103(7):1039-44. Epub 2009 May 13. PubMed PMID: 19501911.

48: Sugiyama T. [Second-line treatment using novel chemotherapeutic and biologic

agents]. Gan To Kagaku Ryoho. 2009 May;36(5):730-5. Japanese. PubMed PMID: 19461172.

49: Minegishi Y, Takenaka K, Mizutani H, Sudoh J, Noro R, Okano T, Azuma A, Yoshimura A, Ando M, Tsuboi E, Kudoh S, Gemma A. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med. 2009;48(9):665-72. Epub 2009 May 1. PubMed PMID: 19420811.

50: Hsu SH, Leu YL, Hu JW, Fang JY. Physicochemical characterization and drug release of thermosensitive hydrogels composed of a hyaluronic acid/pluronic f127

graft. Chem Pharm Bull (Tokyo). 2009 May;57(5):453-8. PubMed PMID: 19420774.

51: Lau D, Huynh M, Johl J. A population-based clinical trial of irinotecan and Carboplatin. J Oncol. 2009;2009:458528. Epub 2009 Apr 23. PubMed PMID: 19404408;

PubMed Central PMCID: PMC2673471.

52: Hamidovic A, Hahn K, Kolesar J. Clinical significance of ABCB1 genotyping in

oncology. J Oncol Pharm Pract. 2010 Mar;16(1):39-44. Epub 2009 Apr 28. PubMed PMID: 19401306; PubMed Central PMCID: PMC2894614.

53: VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009 Apr;8(4):930-9. PubMed PMID: 19372566.

54: Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and

advanced non-small-cell lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S7-16. Review. PubMed PMID: 19362948.

55: Ang WH, Brown WW, Lippard SJ. Preparation of mammalian expression vectors incorporating site-specifically platinated-DNA lesions. Bioconjug Chem. 2009 May

20;20(5):1058-63. PubMed PMID: 19351185; PubMed Central PMCID: PMC2765503.

56: Ohba T, Yamasaki T, Endo Y, Furuie M, Ohtani Y, Inase N, Yoshizawa Y. A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer. J Chemother. 2009 Feb;21(1):80-5. PubMed PMID: 19297278.

57: Samejima J, Adachi H, Kawamoto M, Saeki H, Kato N, Fujisawa J, Matsukawa H, Rino Y, Masuda M. [Rectal perforation in a patient treated with combination chemotherapy for lung cancer]. Gan To Kagaku Ryoho. 2009 Feb;36(2):301-4. Japanese. PubMed PMID: 19223751.

58: Rapidis A, Sarlis N, Lefebvre JL, Kies M. Docetaxel in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag. 2008 Oct;4(5):865-86. PubMed PMID: 19209269; PubMed Central PMCID: PMC2621396.

59: Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi

K. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol. 2009 Apr;20(4):703-8. Epub 2009 Jan 29. PubMed PMID: 19179557.

60: Singh AP, Singh RK, Kim KK, Satyan KS, Nussbaum R, Torres M, Brard L, Vorsa N. Cranberry proanthocyanidins are cytotoxic to human cancer cells and sensitize

platinum-resistant ovarian cancer cells to paraplatin. Phytother Res. 2009 Aug;23(8):1066-74. PubMed PMID: 19172579; PubMed Central PMCID: PMC2873024.

61: Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Sato S, Naniwa J, Uegaki K, Nonaka M, Terakawa N. Combination chemotherapy of oxaliplatin and 5-fluorouracil

may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009 Mar;100(3):546-51. Epub 2008 Dec 19. PubMed

PMID: 19154404.

62: Tanaka T, Umesaki N. Danazol enhances Fas-mediated apoptosis in human endometrial epithelial cells within normal physiology. Int J Mol Med. 2009 Feb;23(2):237-43. PubMed PMID: 19148548.

63: Lucas MF, Pavelka M, Alberto ME, Russo N. Neutral and acidic hydrolysis reactions of the third generation anticancer drug oxaliplatin. J Phys Chem B. 2009 Jan 22;113(3):831-8. PubMed PMID: 19143575.

64: McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan;8(1):10-6. Review. PubMed PMID: 19139108; PubMed Central PMCID: PMC2651829.

65: Di Pasqua AJ, Centerwall CR, Kerwood DJ, Dabrowiak JC. Formation of carbonato and hydroxo complexes in the reaction of platinum anticancer drugs with carbonate. Inorg Chem. 2009 Feb 2;48(3):1192-7. PubMed PMID: 19113934.

66: Konings IR, Engels FK, Sleijfer S, Verweij J, Wiemer EA, Loos WJ. Application of prolonged microdialysis sampling in carboplatin-treated cancer patients. Cancer Chemother Pharmacol. 2009 Aug;64(3):509-16. Epub 2008 Dec 20. PubMed PMID: 19096847; PubMed Central PMCID: PMC2691802.

67: Launay-Vacher V, Isnard-Bagnis C, Janus N, Karie S, Deray G. [Chemotherapy and renal toxicity]. Bull Cancer. 2008 May 28;95 FMC Onco:F96-103. French. PubMed PMID: 18511375.

68: Guggenheim ER, Xu D, Zhang CX, Chang PV, Lippard SJ. Photoaffinity isolation

and identification of proteins in cancer cell extracts that bind to platinum-modified DNA. Chembiochem. 2009 Jan 5;10(1):141-57. PubMed PMID: 19053130; PubMed Central PMCID: PMC2710532.

69: Ningaraj NS, Sankpal UT, Khaitan D, Meister EA, Vats T. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival. Eur J Pharmacol. 2009 Jan 14;602(2-3):188-93. Epub 2008 Nov 9. PubMed PMID: 19027730.

70: Bose RN, Maurmann L, Mishur RJ, Yasui L, Gupta S, Grayburn WS, Hofstetter H,

Salley T. Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells. Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18314-9. Epub 2008 Nov 19. Erratum in: Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1292. Milton, Tara [corrected to Salley, Tara]. PubMed PMID: 19020081; PubMed Central PMCID: PMC2587608.

71: Haxton KJ, Burt HM. Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci. 2009 Jul;98(7):2299-316. Review. PubMed PMID: 19009590.

72: Kruse GB, Amonkar MM, Smith G, Skonieczny DC, Stavrakas S. Analysis of costs

associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008 Nov-Dec;14(9):844-57. PubMed PMID: 19006441.

73: Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008 Nov 1;113(9):2512-7. PubMed PMID: 18816622.

74: Ozensoy Guler O, Arslan O, Kockar F. Differential in vitro inhibitory effects of anticancer drugs on tumor-associated carbonic anhydrase isozymes CA IX and CA

XII. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):335-40. PubMed PMID: 18806891.

75: Ono A, Yamamoto N. [Advances in chemotherapy for lung cancer]. Gan To Kagaku

Ryoho. 2008 Sep;35(9):1475-81. Japanese. PubMed PMID: 18799900.

76: Yamazaki H, Shimizu M, Murayama N, Tanaka K, Nion S, Cecchelli R. Increased transendothelial permeability of anti-cancer agent carboplatin with the aid of hyperbaric oxygenation. Xenobiotica. 2008 Oct;38(10):1298-304. PubMed PMID: 18798124.

77: Thomadaki H, Scorilas A. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin,

doxorubicin, etoposide and taxol. Biol Chem. 2008 Nov;389(11):1427-34. PubMed PMID: 18783338.

78: Pédeboscq S, L'Azou B, Passagne I, De Giorgi F, Ichas F, Pometan JP, Cambar J. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. J Exp Ther Oncol. 2008;7(2):99-111. PubMed PMID: 18771084.

79: Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H; AOCS Study Group, Harnett PR, Brown R, DeFazio A, Chenevix-Trench G. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 2008 Sep 1;14(17):5594-601. PubMed PMID: 18765553.

80: Murayama T, Kawasoe Y, Yamashita Y, Ueno Y, Minami S, Yokouchi M, Komiya S. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res. 2008 Jul-Aug;28(4B):2147-54. PubMed PMID: 18751388.

81: Liu W, Chen X, Xie M, Lou L, Ye Q, Yu Y, Hou S. Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes. J

Inorg Biochem. 2008 Oct;102(10):1942-6. Epub 2008 Jul 11. PubMed PMID: 18707762.

82: Cheng T. Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. Curr Opin Support Palliat Care. 2008 Sep;2(3):153-60. Review. PubMed PMID: 18685414.

83: Wheate NJ. Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils. J Inorg Biochem. 2008 Dec;102(12):2060-6. Epub 2008 Jun 20. Review. PubMed PMID: 18653238.

84: Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, Goh BC, Holford NH. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res. 2008 Jul 1;14(13):4213-8. PubMed PMID: 18594002.

85: Lu W, Li YH, He XF, Zhao JB, Chen Y, Mei QL. Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. Cardiovasc Intervent Radiol. 2008 Nov-Dec;31(6):1133-40. Epub

2008 Jun 27. PubMed PMID: 18584240.

86: Tanaka T, Toujima S, Utsunomiya T, Yukawa K, Umesaki N. Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery. Oncol Rep. 2008 Jul;20(1):13-23. PubMed PMID: 18575713.

87: Iranzo V, Bremnes RM, Almendros P, Gavilá J, Blasco A, Sirera R, Camps C. Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer. Lung Cancer. 2009 Jan;63(1):63-7. Epub 2008 Jun 11. PubMed PMID: 18550204.

88: Zhang J, Liu L, Gong Y, Zheng X, Yang M, Cui J, Shen S. Synthesis, characterization and antitumor activity of new type binuclear platinum(II) complexes. Eur J Med Chem. 2009 May;44(5):2322-7. Epub 2008 Apr 27. PubMed PMID:

18524422.

89: Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 2008 Jun;18(6):515-23. PubMed PMID: 18496131.

90: Chen T, Li M, Zhang R, Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med. 2009 Jul;13(7):1358-70. Epub 2008 May 3. PubMed PMID: 18466355.

91: Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol. 2008 Apr;13(2):112-6. Epub 2008 May 8. Review. PubMed PMID: 18463953.

92: Liu W, Qing C, Chen X, Ye Q, Yu Y, Hou S. Preparation, characterization and in vitro anticancer activity of platinum(II) complexes with N-Cyclohexyl-1,3-propanediamine as the carrier. Chem Pharm Bull (Tokyo). 2008 May;56(5):659-62. PubMed PMID: 18451553.

93: Han SS, Choi SH, Lee YK, Kim JW, Park NH, Song YS, Lee HP, Kang SB. Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer. Cancer Invest. 2008 May;26(4):426-30. PubMed PMID: 18443964.

94: Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, Petrovich SV. Dose enhancement effect of anticaner drugs associated with increased temperature in vitro. Exp Oncol. 2008 Mar;30(1):56-9. PubMed PMID: 18438342.

95: Fujiwara K. Can carboplatin replace cisplatin for intraperitoneal use? Int J

Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:29-32. Review. PubMed PMID: 18336396.

96: Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, Berger W. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat. 2008 Feb-Apr;11(1-2):1-16. Epub 2008 Apr 3. Review. PubMed PMID: 18394950.

97: Gabbiani C, Casini A, Mastrobuoni G, Kirshenbaum N, Moshel O, Pieraccini G, Moneti G, Messori L, Gibson D. Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis. J Biol Inorg Chem. 2008 Jun;13(5):755-64. Epub 2008 Mar 19. PubMed PMID: 18350322.

98: Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):285-95. Review. PubMed PMID: 18221042.

99: Xiong ZP, Zhang YD, Huang F, Liang ZY. [Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):623-5. Chinese. PubMed PMID: 18210886.

100: Parolaro D, Massi P. Cannabinoids as potential new therapy for the treatment of gliomas. Expert Rev Neurother. 2008 Jan;8(1):37-49. Review. PubMed PMID: 18088200.

101: Malinowska K, Modranka R, Kedziora J. [Anticancer drugs used in medicine and being in clinical research]. Pol Merkur Lekarski. 2007 Sep;23(135):165-9. Polish. PubMed PMID: 18080687.

102: Coley HM, Sarju J, Wagner G. Synthesis and characterization of platinum(II)

oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines. J Med Chem. 2008 Jan 10;51(1):135-41. Epub 2007 Dec 12. PubMed PMID: 18072719.

103: Tanaka T, Yukawa K, Umesaki N. Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro. Eur J Gynaecol Oncol. 2007;28(5):352-5. PubMed PMID: 17966212.

104: Yu Y, Lou LG, Liu WP, Zhu HJ, Ye QS, Chen XZ, Gao WG, Hou SQ. Synthesis and

anticancer activity of lipophilic platinum(II) complexes of 3,5-diisopropylsalicylate. Eur J Med Chem. 2008 Jul;43(7):1438-43. Epub 2007 Sep

19. PubMed PMID: 17959272.

105: Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007 Oct 20;25(30):4707-13. PubMed PMID: 17947717.

106: He H, Huang JQ, Ping FY, Chen GF, Zhang SZ. Deep lingual arterial chemoembolization of tongue carcinoma with microcapsuled anticancer drug. J Zhejiang Univ Sci B. 2007 Oct;8(10):704-8. PubMed PMID: 17910111; PubMed Central

PMCID: PMC1997222.

107: Herst PM, Petersen T, Jerram P, Baty J, Berridge MV. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007

Dec 3;74(11):1587-95. Epub 2007 Aug 19. PubMed PMID: 17904534.

108: Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol. 2007 Nov 9;373(5):1123-40. Epub 2007 Aug 23. PubMed PMID: 17900616; PubMed Central PMCID: PMC2129172.

109: Pavelka M, Lucas MF, Russo N. On the hydrolysis mechanism of the second-generation anticancer drug carboplatin. Chemistry. 2007;13(36):10108-16. PubMed PMID: 17896336.

110: Woo S, Krzyzanski W, Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol. 2008 Jun;62(1):123-33. Epub 2007 Sep 22. PubMed PMID: 17891399; PubMed Central PMCID:

PMC2671004.

111: Pang SK, Yu CW, Au-Yeung SC, Ho YP. DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes. Biochem Biophys Res Commun. 2007 Nov 9;363(1):235-40. Epub 2007 Sep 7. PubMed PMID: 17868646.

112: Lu W, Li YH, Yu ZJ, He XF, Chen Y, Zhao JB, Zhu ZY. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology. 2007 Jul-Aug;54(77):1499-502. PubMed PMID: 17708284.

113: Yang Z, Wang X, Diao H, Zhang J, Li H, Sun H, Guo Z. Encapsulation of platinum anticancer drugs by apoferritin. Chem Commun (Camb). 2007 Sep 7;(33):3453-5. Epub 2007 May 17. PubMed PMID: 17700879.

114: Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35. Epub 2007 Jul 4. Review. PubMed PMID: 17692427.

115: Matei D. Novel agents in ovarian cancer. Expert Opin Investig Drugs. 2007 Aug;16(8):1227-39. Review. PubMed PMID: 17685871.

116: Di Pasqua AJ, Goodisman J, Kerwood DJ, Toms BB, Dabrowiak JC. Modification of carboplatin by Jurkat cells. J Inorg Biochem. 2007 Oct;101(10):1438-41. Epub 2007 Jun 21. PubMed PMID: 17655933.

117: Sugiyama T, Yoshizaki A, Hatayama S. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist]. Gan To Kagaku Ryoho. 2007 Jul;34(7):1011-6. Japanese. PubMed PMID: 17637537.

118: Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007 Aug;7(8):573-84. Epub 2007 Jul 12. Review. PubMed PMID: 17625587.

119: Krupka TM, Weinberg BD, Wu H, Ziats NP, Exner AA. Effect of intratumoral injection of carboplatin combined with pluronic P85 or L61 on experimental colorectal carcinoma in rats. Exp Biol Med (Maywood). 2007 Jul;232(7):950-7. PubMed PMID: 17609512.

120: Cini R, Tamasi G, Defazio S, Hursthouse MB. Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex. J Inorg Biochem. 2007 Aug;101(8):1140-52. Epub 2007 May 10. PubMed PMID: 17592742.

121: Thomas F, Séronie-Vivien S, Malard L, Chatelut E. [Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys]. Therapie. 2007 Mar-Apr;62(2):121-7. Epub 2007 Jun 21. French. PubMed PMID: 17582313.

122: Lang DS, Droemann D, Schultz H, Branscheid D, Martin C, Ressmeyer AR, Zabel

P, Vollmer E, Goldmann T. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respir Res. 2007 Jun 14;8:43. PubMed PMID: 17567922; PubMed Central PMCID: PMC1913052.

123: Hoshida Y, Moriyama M, Otsuka M, Kato N, Taniguchi H, Shiratori Y, Seki N, Omata M. Gene expressions associated with chemosensitivity in human hepatoma cells. Hepatogastroenterology. 2007 Mar;54(74):489-92. PubMed PMID: 17523305.

124: Loh GW, Ting LS, Ensom MH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet. 2007;46(6):471-94. Review. PubMed PMID: 17518507.

125: Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller

RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3605-10. Epub 2007 May 17. Erratum in: Clin Cancer Res. 2007 Oct 15;13(20):6245. Ramananthan, Ramesh K [corrected to Ramanathan, Ramesh K]. PubMed PMID: 17510206.

126: Ono A, Kanno H, Hayashi A, Nishimura S, Kyuma Y, Sato H, Ito S, Shimizu N, Chang CC, Gondo G, Yamamoto I, Sasaki T, Tanaka M. Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors. Int J Clin Oncol. 2007 Apr;12(2):125-30. Epub 2007 Apr 27. PubMed PMID: 17443280.

127: Peacock AF, Habtemariam A, Moggach SA, Prescimone A, Parsons S, Sadler PJ. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity. Inorg Chem. 2007 May 14;46(10):4049-59. Epub 2007 Apr 19. PubMed PMID: 17441712.

128: Tao Z, Goodisman J, Penefsky HS, Souid AK. Caspase activation by anticancer

drugs: the caspase storm. Mol Pharm. 2007 Jul-Aug;4(4):583-95. Epub 2007 Apr 17.

PubMed PMID: 17439154.

129: Yoneda S. [Outpatient chemotherapy for lung cancer]. Gan To Kagaku Ryoho. 2007 Apr;34(4):533-7. Japanese. PubMed PMID: 17431337.

130: Wang X, Au-Yeung SC, Ho YP. Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats. J Inorg Biochem. 2007 Jun;101(6):909-17. Epub 2007 Mar 4. PubMed PMID: 17428541.

131: Thomadaki H, Scorilas A. Breast cancer cells response to the antineoplastic

agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. PubMed PMID: 17404015.

132: Moon YW, Choi SH, Kim YT, Sohn JH, Chang J, Kim SK, Park MS, Chung KY, Lee HJ, Kim JH. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer. 2007 May 1;109(9):1829-35. PubMed PMID: 17366594.

133: Clerico A, Cappelli C, Ragni G, Caroli S, De Ioris MA, Sordi A, Petrucci F,

Bocca B, Alimonti A. Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry. Ann Ist Super

Sanita. 2006;42(4):461-8. PubMed PMID: 17361071.

134: Melliou A, Theocharidis G, Helis L, Makridis J, Patakiouta F, Kouroussis C.

Carcinoma of sigmoid colon after ureterosigmoidostomy. J BUON. 2005 Oct-Dec;10(4):551-553. PubMed PMID: 17357215.

135: Kwon YE, Park JY, Kim WK. In vitro histoculture drug response assay and in vivo blood chemistry of a novel Pt(IV) compound, K104. Anticancer Res. 2007 Jan-Feb;27(1A):321-6. PubMed PMID: 17352249.

136: Geromichalos GD, Katsoulos GA, Trafalis DT, Hadjikostas CC, Papageorgiou A.

Synergistic interaction between a novel mixed ligand copper(II) chelate complex and a panel of anticancer agents in T47D human breast cancer cells in vitro. J BUON. 2005 Apr-Jun;10(2):235-40. PubMed PMID: 17343335.

137: Berger I, Nazarov AA, Hartinger CG, Groessl M, Valiahdi SM, Jakupec MA, Keppler BK. A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? ChemMedChem. 2007 Apr;2(4):505-14. PubMed PMID: 17340670.

138: Wang H, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Dexamethasone as

a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics.

Int J Oncol. 2007 Apr;30(4):947-53. PubMed PMID: 17332934.

139: Muramatsu T, Shinozuka T, Hirasawa T, Tsukada H, Maeda H, Miyamoto T, Murakami M, Kajiwara H, Yasuda M, Osamura RY, Mikami M. Treatment strategy for recurrent and refractory epithelial ovarian cancer: efficacy of high-dose chemotherapy with hematopoietic stem cell transplantation. Acta Histochem Cytochem. 2006 Jul 1;39(3):61-7. Epub 2006 May 26. PubMed PMID: 17327925; PubMed

Central PMCID: PMC1790973.

140: Peacock AF, Parsons S, Sadler PJ. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. J Am Chem Soc. 2007 Mar 21;129(11):3348-57. Epub 2007 Feb 24. PubMed PMID: 17319668.

141: Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):739-63. Epub 2007 Feb 16. Review. PubMed PMID: 17309673.

142: Yamagami W, Banno K, Kawaguchi M, Yanokura M, Kuwabara Y, Hirao N, Susumu N, Tsukazaki K, Aoki D. Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report. Chemotherapy. 2007;53(2):137-41. Epub 2007 Feb 16. PubMed PMID: 17308380.

143: Dittrich C, Zandvliet AS, Gneist M, Huitema AD, King AA, Wanders J. A phase

I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer. 2007 Feb 26;96(4):559-66. Epub 2007 Feb 6. PubMed PMID: 17285128; PubMed

Central PMCID: PMC2360043.

144: Ott I, Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med Chem. 2007 Jan;7(1):95-110. Review. PubMed PMID: 17266507.

145: Galanski M, Keppler BK. Searching for the magic bullet: anticancer platinum

drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med Chem. 2007 Jan;7(1):55-73. Review. PubMed PMID: 17266505.

146: Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007 Jan;7(1):3-18. Review. PubMed PMID: 17266502.

147: Tsurumaru D, Kuroiwa T, Yabuuchi H, Hirata H, Higaki Y, Tomita K. Efficacy of intra-arterial infusion chemotherapy for head and neck cancers using coaxial catheter technique: initial experience. Cardiovasc Intervent Radiol. 2007 Mar-Apr;30(2):207-11. PubMed PMID: 17216381.

148: Styczynski J, Olszewska-Slonina D, Kolodziej B, Napieraj M, Wysocki M. Activity of bortezomib in glioblastoma. Anticancer Res. 2006 Nov-Dec;26(6B):4499-503. PubMed PMID: 17201170.

149: Miki T, Mizutani Y, Akaza H, Ozono S, Tsukamoto T, Terachi T, Naito K, Nonomura N, Hara I, Yoshida O; Japan Blood Cell Transplantation Study Group for Testicular Germ Cell Tumor. Long-term results of first-line sequential high-dose

carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor. Int J Urol. 2007 Jan;14(1):54-9. PubMed PMID: 17199861.

150: Casini A, Mastrobuoni G, Temperini C, Gabbiani C, Francese S, Moneti G, Supuran CT, Scozzafava A, Messori L. ESI mass spectrometry and X-ray diffraction

studies of adducts between anticancer platinum drugs and hen egg white lysozyme.

Chem Commun (Camb). 2007 Jan 14;(2):156-8. Epub 2006 Oct 26. PubMed PMID: 17180231.

151: Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, Jiang SW. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and

microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther. 2006 Nov;5(11):2767-76. PubMed PMID: 17121923.

152: Riely GJ, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.

Lung Cancer. 2007 Feb;55(2):181-5. Epub 2006 Nov 7. PubMed PMID: 17092603.

153: Fujiwara K. [Antitumor effects and clinical problems of transcatheter intraarterial infusion for uterine cervical cancer]. Gan To Kagaku Ryoho. 2006 Sep;33(9):1236-40. Japanese. PubMed PMID: 16969017.

154: Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.

PubMed PMID: 16951202; PubMed Central PMCID: PMC2775093.

155: Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, Schellens JH, Beijnen JH. Sensitive inductively coupled plasma mass spectrometry assay for the

determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom. 2006 Sep;41(9):1186-94. PubMed PMID: 16929560.

156: Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006 Aug;5(8):2086-95. PubMed PMID: 16928830.

157: Hamelers IH, van Loenen E, Staffhorst RW, de Kruijff B, de Kroon AI. Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol Cancer Ther. 2006 Aug;5(8):2007-12. PubMed PMID: 16928821.

158: To KK, Au-Yeung SC, Ho YP. Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles. Anticancer Drugs. 2006 Jul;17(6):673-83. PubMed PMID: 16917213.

159: Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86. Epub 2006 Aug 16. PubMed PMID: 16914559.

160: Lee SY, Jeon DG, Cho WH, Song WS, Kim MB, Park JH. Preliminary study of chemosenstivity tests in osteosarcoma using a histoculture drug response assay. Anticancer Res. 2006 Jul-Aug;26(4B):2929-32. PubMed PMID: 16886615.

161: Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H, Furukawa Y. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally

named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs. 2007 Feb;25(1):31-40. PubMed PMID: 16865529.

162: Gemma A, Li C, Sugiyama Y, Matsuda K, Seike Y, Kosaihira S, Minegishi Y, Noro R, Nara M, Seike M, Yoshimura A, Shionoya A, Kawakami A, Ogawa N, Uesaka H,

Kudoh S. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer. 2006 Jun 30;6:174. PubMed PMID: 16813650; PubMed Central PMCID: PMC1533844.

163: Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer. 2006 Jul 3;95(1):42-8. PubMed PMID: 16804528; PubMed Central PMCID: PMC2360484.

164: Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol Ther. 2006 Aug;5(8):943-9. Epub 2006 Aug 2. PubMed PMID: 16775422.

165: Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of

breast cancer cells in vitro and in vivo. Cancer Res. 2006 Jun 1;66(11):5836-46.

PubMed PMID: 16740723.

166: Takizawa M, Kawakami K, Obata T, Matsumoto I, Ohta Y, Oda M, Sasaki T, Watanabe G. In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol Rep. 2006 Jun;15(6):1533-9. PubMed PMID: 16685392.

167: Ludwig T, Fakih S, Bertram H, Krebs B, Oberleithner H. New imidazole-coordinated chemotherapeutics with low epithelial toxicity. Cell Biochem Biophys. 2006;45(1):31-41. PubMed PMID: 16679562.

168: Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, Tranchand B, Monjanel-Mouterde S, Guillet P, Nicoara A, Baciuchka M, Bagarry-Liegey D, Lacarelle B, Noble A, Durand A, Favre R. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit. 2006 Apr;28(2):212-8. PubMed PMID: 16628133.

169: Bouvet D, Michalowicz A, Crauste-Manciet S, Brossard D, Provost K. EXAFS and IR structural study of platinum-based anticancer drugs' degradation by diethyl dithiocarbamate. Inorg Chem. 2006 Apr 17;45(8):3393-8. PubMed PMID: 16602799.

170: Kikkawa F, Nawa A, Ino K, Shibata K, Kajiyama H, Nomura S. Advances in treatment of epithelial ovarian cancer. Nagoya J Med Sci. 2006 Jan;68(1-2):19-26. Review. PubMed PMID: 16579172.

171: Tanaka T, Bai T, Yukawa K, Umesaki N. Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro. Oncol Rep. 2006 Apr;15(4):939-47. PubMed PMID: 16525683.

172: Mijatovic T, Op De Beeck A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther. 2006 Feb;5(2):391-9. PubMed PMID: 16505114.

173: Masubuchi Y, Kawasaki M, Horie T. Down-regulation of hepatic cytochrome P450 enzymes associated with cisplatin-induced acute renal failure in male rats. Arch

Toxicol. 2006 Jun;80(6):347-53. Epub 2006 Feb 17. PubMed PMID: 16485119.

174: Labanauskiene J, Didziapetriene J, Aleknavicius E. [The role of electroporation in increasing the effectiveness of anticancer drugs]. Medicina (Kaunas). 2006;42(1):33-7. Lithuanian. PubMed PMID: 16467611.

175: Yu CW, Li KK, Pang SK, Au-Yeung SC, Ho YP. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1686-91. Epub 2006 Jan 4. PubMed PMID: 16386904.

176: de Jonge ME, Huitema AD, van Dam SM, Rodenhuis S, Beijnen JH. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Ther Drug Monit. 2005 Dec;27(6):756-65. PubMed PMID: 16306851.

177: Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, Christofilakis C, Xenidis N, Georgoulias V, Polyzos A. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. Oncology. 2005;69(4):348-53. Epub 2005 Nov 16. PubMed PMID: 16293974.

178: Li W, Lam M, Choy D, Birkeland A, Sullivan ME, Post JM. Human primary renal

cells as a model for toxicity assessment of chemo-therapeutic drugs. Toxicol In Vitro. 2006 Aug;20(5):669-76. Epub 2005 Nov 10. PubMed PMID: 16289493.

179: Kondo C, Shibata K, Terauchi M, Kajiyama H, Ino K, Nomura S, Nawa A, Mizutani S, Kikkawa F. A novel role for placental leucine aminopeptidase (P-LAP)

as a determinant of chemoresistance in endometrial carcinoma cells. Int J Cancer. 2006 Mar 15;118(6):1390-4. PubMed PMID: 16187279.

180: Klein A, He X, Roche M, Mallett A, Duska L, Supko JG, Seiden MV. Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming

a fermented soy therapy. Gynecol Oncol. 2006 Jan;100(1):205-9. Epub 2005 Sep 19.

PubMed PMID: 16171852.

181: Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, Bian JS, Huang M, Zhu YZ, Xiong W, Li X, Zhou S. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res. 2005 Nov;22(11):1837-53. PubMed PMID: 16132345.

182: Danford AJ, Wang D, Wang Q, Tullius TD, Lippard SJ. Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc Natl

Acad Sci U S A. 2005 Aug 30;102(35):12311-6. Epub 2005 Aug 22. PubMed PMID: 16116097; PubMed Central PMCID: PMC1194956.

183: Galanski M, Jakupec MA, Keppler BK. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical

approaches. Curr Med Chem. 2005;12(18):2075-94. Review. PubMed PMID: 16101495.

184: Ratanaphan A, Canyuk B, Wasiksiri S, Mahasawat P. In vitro platination of human breast cancer suppressor gene1 (BRCA1) by the anticancer drug carboplatin.

Biochim Biophys Acta. 2005 Sep 15;1725(2):145-51. PubMed PMID: 16099593.

185: Witte AB, Anestål K, Jerremalm E, Ehrsson H, Arnér ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005 Sep 1;39(5):696-703. PubMed PMID: 16085187.

186: Perry WL 3rd, Shepard RL, Sampath J, Yaden B, Chin WW, Iversen PW, Jin S, Lesoon A, O'Brien KA, Peek VL, Rolfe M, Shyjan A, Tighe M, Williamson M, Krishnan V, Moore RE, Dantzig AH. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. PubMed PMID: 16061639.

187: Kang YH, Lee KA, Ryu CJ, Lee HG, Lim JS, Park SN, Paik SG, Yoon DY. Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells. Cancer Lett. 2006 Jun 8;237(1):33-44. Epub 2005 Jul 12. PubMed PMID: 16019139.

188: Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. Chemotherapy for non-small cell lung cancer in elderly patients. Chest. 2005 Jul;128(1):132-9. PubMed PMID: 16002926.

189: Wheate NJ, Collins JG. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr Med Chem Anticancer Agents. 2005 May;5(3):267-79. Review. PubMed PMID: 15992354.

190: Furonaka M, Miyazaki M, Nakajima M, Hirata S, Fujitaka K, Kondo K, Yokoyama

A, Maeda H, Kohno N. Neutropenic enterocolitis in lung cancer: a report of two cases and a review of the literature. Intern Med. 2005 May;44(5):467-70. Review.

PubMed PMID: 15942096.

191: Kikuchi Y, Kita T, Takano M, Kudoh K, Yamamoto K. Treatment options in the management of ovarian cancer. Expert Opin Pharmacother. 2005 May;6(5):743-54. Review. PubMed PMID: 15934901.

192: Heymach JV. ZD6474--clinical experience to date. Br J Cancer. 2005 Jun;92 Suppl 1:S14-20. Review. PubMed PMID: 15928653; PubMed Central PMCID: PMC2362057.

193: Liu S, Liu Y, Li J, Guo M, Nie L, Yao S. Study on the interaction between DNA and protein induced by anticancer drug carboplatin. J Biochem Biophys Methods. 2005 May 30;63(2):125-36. PubMed PMID: 15896850.

194: Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005 Feb;41(2):107-27. Review. PubMed PMID: 15821783.

195: Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005 Apr;4(4):307-20. Review. PubMed PMID: 15789122.

196: Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, Ueoka H,

Ohnoshi T, Tanimoto M. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. Anticancer Res. 2004 Nov-Dec;24(6):3911-6. PubMed PMID: 15736431.

197: Kunishio K, Okada M, Matsumoto Y, Nagao S. Preliminary individual adjuvant chemotherapy for primary central nervous system lymphomas based on the expression of drug-resistance genes. Brain Tumor Pathol. 2004;21(2):57-61. PubMed PMID: 15700834.

198: Koshida K, Egawa M, Imao T, Mizokami A, Namiki M, Endo Y, Sasaki T. In vitro chemosensitivity test for human genito-urinary tumors using collagen gel matrix.

Int J Urol. 2005 Jan;12(1):67-72. PubMed PMID: 15661056.

199: Hanauske AR, Dittrich C, Otero J. Overview of phase I/II pemetrexed studies. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):18-25. Review. PubMed PMID: 15655932.

200: Min J, Traynor D, Stegner AL, Zhang L, Hanigan MH, Alexander H, Alexander S. Sphingosine kinase regulates the sensitivity of Dictyostelium discoideum cells to the anticancer drug cisplatin. Eukaryot Cell. 2005 Jan;4(1):178-89. PubMed PMID:

15643073; PubMed Central PMCID: PMC544159.

201: Endo T, Yoshikawa M, Ebara M, Kato K, Sunaga M, Fukuda H, Hayasaka A, Kondo

F, Sugiura N, Saisho H. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol. 2004 Dec;39(12):1196-201. PubMed PMID: 15622485.

202: Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology

and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23. Review. PubMed PMID: 15607932.

203: Mishima K, Nariai Y, Yoshimura Y. Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression. Oral Oncol. 2005 Jan;41(1):77-81. PubMed

PMID: 15598589.

204: Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res. 2004 Dec 1;10(23):8048-58. PubMed PMID: 15585640.

205: Kogo M, Saito Y, Kashiwabara Y, Koichi K, Ichikawa I, Horichi N, Imai T, Adachi M, Murayama J, Kiuchi Y. [Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer]. Yakugaku Zasshi. 2004 Dec;124(12):973-81. Japanese. PubMed PMID: 15577267.

206: Warnecke A, Fichtner I, Garmann D, Jaehde U, Kratz F. Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs. Bioconjug Chem. 2004 Nov-Dec;15(6):1349-59. PubMed PMID: 15546202.

207: Wigington DP, Urben CM, Strugnell SA, Knutson JC. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Anticancer Res. 2004 Sep-Oct;24(5A):2905-12. PubMed PMID: 15517895.

208: Chintagumpala M, Blaney SM, Bomgaars LR, Aleksic A, Kuttesch JF, Klenke RA,

Berg SL. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 1;22(21):4394-400. PubMed PMID: 15514381.

209: Bosanquet AG, Bell PB. Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells. J Exp Ther Oncol. 2004 Jul;4(2):145-54. PubMed PMID: 15500009.

210: Choi CH, Cha YJ, An CS, Kim KJ, Kim KC, Moon SP, Lee ZH, Min YD. Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein. Cancer Cell Int. 2004 Oct 19;4(1):6.

PubMed PMID: 15494073; PubMed Central PMCID: PMC533863.

211: Chaney SG, Campbell SL, Temple B, Bassett E, Wu Y, Faldu M. Protein interactions with platinum-DNA adducts: from structure to function. J Inorg Biochem. 2004 Oct;98(10):1551-9. PubMed PMID: 15458816.

212: Riedel F, Götte K, Goessler U, Sadick H, Hörmann K. Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines. Anticancer Res. 2004 Jul-Aug;24(4):2179-83. PubMed PMID: 15330158.

213: Ludwig T, Fakih S, Krebs B, Oberleithner H. Platinum complex cytotoxicity tested by the electrical resistance breakdown assay. Cell Physiol Biochem. 2004;14(4-6):425-30. PubMed PMID: 15319546.

214: Miyazaki M, Oguri T, Kurata T, Takahashi T, Daga H, Fujitaka K, Isobe T, Nakajima M, Fujiwara Y, Kohno N. Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes. Anticancer Res. 2004 May-Jun;24(3b):1911-4. PubMed PMID: 15274375.

215: Aronov O, Horowitz AT, Gabizon A, Fuertes MA, Pérez JM, Gibson D. Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues. Bioconjug Chem. 2004 Jul-Aug;15(4):814-23. PubMed PMID: 15264869.

216: Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, You HJ. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer

agents. Cancer Res. 2004 Jul 15;64(14):4849-57. Erratum in: Cancer Res. 2004 Nov

15;64(22):8484. PubMed PMID: 15256455.

217: Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung

cancer. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4245s-4248s. Review. PubMed PMID: 15217967.

218: Chen J, Wang L, Yao Q, Ling R, Li K, Wang H. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer. Breast Cancer Res. 2004;6(4):R474-7. Epub 2004 Jun 17. PubMed PMID: 15217515; PubMed Central PMCID: PMC468670.

219: Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53. Epub 2004 Jun 12. PubMed PMID: 15197486.

220: Deng HB, Adikari M, Parekh HK, Simpkins H. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol. 2004 Oct;54(4):301-7. Epub 2004 May 11. PubMed PMID: 15138708.

221: Veal GJ, English MW, Grundy RG, Shakespeare C, Glaser A, Waters F, Holden V, O'Meara A, Michalski A, Howe K, Cole S, Boddy AV. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemother Pharmacol. 2004 Oct;54(4):295-300. Epub 2004 May 4. PubMed PMID: 15133627.

222: Husain K, Scott B, Whitworth C, Rybak LP. Time response of carboplatin-induced hearing loss in rat. Hear Res. 2004 May;191(1-2):110-8. PubMed PMID: 15109710.

223: Liang XJ, Shen DW, Gottesman MM. Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells. Mol Pharmacol. 2004 May;65(5):1217-24. PubMed PMID: 15102950.

224: Marsh JW, Donovan M, Burholt DR, George LD, Kornblith PL. Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents. J Neurooncol. 2004 Jan;66(1-2):81-90. PubMed PMID: 15015773.

225: Janmaat ML, Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc). 2003;39 Suppl C:61-80. Review. PubMed PMID: 14988746.

226: Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep. 2004 Mar;11(3):559-95. Review. PubMed PMID: 14767508.

227: Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res. 2004 Jan 1;64(1):356-62. PubMed PMID: 14729645.

228: Lu W, Li Y, He X, Chen Y. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology. 2003 Nov-Dec;50(54):2079-83. PubMed PMID: 14696468.

229: Inoue A, Saijo Y, Kikuchi T, Gomi K, Suzuki T, Maemondo M, Miki M, Sato T, Nukiwa T. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol. 2004 Jan;15(1):51-4. PubMed PMID: 14679119.

230: Rosell R, Taron M, Camps C, López-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc). 2003 Oct;39(10):775-86. Review. PubMed PMID: 14668933.

231: Vermorken JB. The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:178-84. Review. PubMed PMID: 14656277.

232: Matsunaga T, Kogawa K, Fujimi A, Takizawa K, Takahira N, Takemoto N, Tanaka

I, Akiyama T, Sato T, Takayama T, Terui T, Sakamaki S, Niitsu Y. C(H)OP refractory chronic lymphocytic leukemia patients in whom salvage chemotherapy chosen by evaluating multiple chemotherapeutic drug-resistant factors was remarkably effective. Int J Clin Oncol. 2003 Oct;8(5):326-31. PubMed PMID: 14586760.

233: Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf. 2003 Nov;2(6):597-607. Review. PubMed PMID: 14585068.

234: Donnelly ET, Kelley M, Rockwell S. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo. Cancer Chemother Pharmacol. 2004 Jan;53(1):43-50. Epub 2003 Oct 22. PubMed PMID: 14574460.

235: Kleine M, Wolters D, Sheldrick WS. The influence of methionine-containing peptides on the reaction of carboplatin with 5'-guanosine monophosphate: a comparison with cisplatin. J Inorg Biochem. 2003 Dec 1;97(4):354-63. PubMed PMID: 14568240.

236: Szymanski-Exner A, Gallacher A, Stowe NT, Weinberg B, Haaga JR, Gao J. Local carboplatin delivery and tissue distribution in livers after radiofrequency ablation. J Biomed Mater Res A. 2003 Nov 1;67(2):510-6. PubMed PMID: 14566792.

237: Goto H, Yang B, Petersen D, Pepper KA, Alfaro PA, Kohn DB, Reynolds CP. Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines. Mol Cancer Ther. 2003 Sep;2(9):911-7. PubMed PMID: 14555710.

238: Husain K, Whitworth C, Hazelrigg S, Rybak L. Carboplatin-induced oxidative injury in rat inferior colliculus. Int J Toxicol. 2003 Sep-Oct;22(5):335-42. PubMed PMID: 14555405.

239: Ningaraj NS, Rao M, Black KL. Calcium-dependent potassium channels as a target protein for modulation of the blood-brain tumor barrier. Drug News Perspect. 2003 Jun;16(5):291-8. PubMed PMID: 12942160.

240: Schmittgen TD, Ju JF, Danenberg KD, Danenberg PV. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs. Int J Oncol. 2003 Sep;23(3):785-9. PubMed PMID: 12888918.

241: Focan C, Focan-Henrard D, Kreutz F, Moeneclaey N. [Chronobiological considerations for the management of human head and neck cancer]. Pathol Biol (Paris). 2003 Jun;51(4):201-3. French. PubMed PMID: 12852988.

242: Sato A, Sakashita A, Taguchi S. [Hypersensitivity reactions to cancer chemotherapeutic agents]. Gan To Kagaku Ryoho. 2003 Jun;30(6):793-800. Review. Japanese. PubMed PMID: 12852346.

243: Adis International Ltd. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Drugs R D. 2003;4(4):243-8. PubMed PMID: 12848590.

244: Pete I, Szánthó A, Mayer A, Thurzó L, Pulay T. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas]. Orv Hetil. 2003 May 11;144(19):919-24. Hungarian. PubMed PMID: 12809068.

245: Miyazaki J, Kawai K. [Prevention and management of nephrotoxicity from anti-cancer agents]. Nippon Rinsho. 2003 Jun;61(6):973-7. Review. Japanese. PubMed PMID: 12806945.

246: Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites.

Ann Oncol. 2003 Jun;14(6):938-45. PubMed PMID: 12796033.

247: Ho YP, Au-Yeung SC, To KK. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev. 2003 Sep;23(5):633-55. Review. PubMed PMID: 12789689.

248: Marimastat: BB 2516, TA 2516. Drugs R D. 2003;4(3):198-203. Review. PubMed PMID: 12757409.

249: Mishima K, Nariai Y, Yoshimura Y. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Int J Cancer. 2003 Jul 10;105(5):593-600. PubMed PMID: 12740905.

250: Fichtner I, Reszka R, Arndt D, Zeisig R. Animal experiments-an essential component for the development of liposomal anticancer agents. J Liposome Res. 2003 Feb;13(1):9-15. Review. PubMed PMID: 12725721.

251: Hotze AC, Bacac M, Velders AH, Jansen BA, Kooijman H, Spek AL, Haasnoot JG,

Reedijk J. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II)

complexes. J Med Chem. 2003 Apr 24;46(9):1743-50. PubMed PMID: 12699392.

252: Svensson K, Larsson C. A protein kinase Cbeta inhibitor attenuates multidrug resistance of neuroblastoma cells. BMC Cancer. 2003 Mar 26;3:10. PubMed PMID: 12697075; PubMed Central PMCID: PMC153510.

253: Mahboobi H, Viarengo A, Colangelo D, Osella D. Effect of metal-based anticancer drugs on wild type and metallothionein null cell lines. Biometals. 2003 Sep;16(3):403-9. PubMed PMID: 12680702.

254: Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003 May;22(5):1169-73. PubMed PMID: 12684687.

255: Gu G, Huang J, He H. Sequential-release of anticancer drugs microcapsulated

with ethylcellulose. Chin Med J (Engl). 2002 Nov;115(11):1730-2. PubMed PMID: 12609096.

256: Moriyama M, Hoshida Y, Otsuka M, Nishimura S, Kato N, Goto T, Taniguchi H, Shiratori Y, Seki N, Omata M. Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol Cancer Ther. 2003 Feb;2(2):199-205. PubMed PMID: 12589037.

257: Boyer MJ, Rivory LP, Clarke SJ. Pemetrexed: single-agent and combination phase I study overview. Semin Oncol. 2002 Dec;29(6 Suppl 18):18-23. Review. PubMed PMID: 12571806.

258: Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002 Aug;16(4):253-62. Review. PubMed PMID: 12570013.

259: Takimoto CH, Diggikar S. Heat shock protein and proteasome targeting agents. Hematol Oncol Clin North Am. 2002 Oct;16(5):1269-85. Review. PubMed PMID: 12512392.

260: Ramalingam S, Belani CP. Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother. 2002 Dec;3(12):1693-709. Review. PubMed PMID: 12472367.

261: Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002 Jan;1(3):227-35. Review. PubMed PMID: 12467217.

262: Husai K, Jagannathan R, Hasan Z, Trammell GL, Rybak LP, Hazelrigg SR, Somani SM. Dose response of carboplatin-induced nephrotoxicity in rats. Pharmacol Toxicol. 2002 Aug;91(2):83-9. PubMed PMID: 12420797.

263: Johansen MJ, Thapar N, Newman RA, Madden T. Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models. J Exp Ther Oncol. 2002 May-Jun;2(3):163-73. PubMed PMID: 12415633.

264: Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics. 2002 Oct;12(7):543-53. PubMed PMID: 12360105.

265: Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, Teicher BA. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer

Res. 2002 Oct 1;62(19):5597-602. PubMed PMID: 12359773.

266: Shen M, Schilder RJ, Obasaju C, Gallo JM. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol. 2002 Sep;50(3):243-50. Epub 2002 Jul 16. PubMed PMID: 12203107.

267: Ishibashi T, Yano Y, Oguma T. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol. 2002 Sep;50(3):230-6. Epub 2002 Jul 3. PubMed PMID: 12203105.

268: Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boemer SA, Atherton P, Ames MM, Kaufmann SH. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients

with advanced cancer. Invest New Drugs. 2002 Aug;20(3):297-304. PubMed PMID: 12201492.

269: Ferrari S, Rovati B, Cucca L, Scarabelli C, Presti M, Beccaria C, Collovà E, Porta C, Danova M. Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study. Oncol Rep. 2002 Sep-Oct;9(5):1107-13. PubMed PMID: 12168081.

270: Chang JY, Liu JF, Juang SH, Liu TW, Chen LT. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res. 2002 Jul 1;62(13):3716-21. PubMed PMID: 12097280.

271: Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, Sadler PJ, Jodrell DI. In vitro and in vivo activity and cross resistance profiles of novel

ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer. 2002 May 20;86(10):1652-7. PubMed PMID: 12085218; PubMed Central PMCID: PMC2746580.

272: Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Kollmannsberger C, Beyer J, Jonas U, Kanz L. Recent strategies for the use of paclitaxel in the treatment of

urological malignancies. World J Urol. 1998;16(2):155-62. Review. PubMed PMID: 12073232.

273: Jansen BA, Brouwer J, Reedijk J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem. 2002 Apr 28;89(3-4):197-202. PubMed PMID: 12062123.

274: Giese B, Deacon GB, Kuduk-Jaworska J, McNaughton D. Density functional theory and surface enhanced Raman spectroscopy characterization of novel platinum drugs. Biopolymers. 2002;67(4-5):294-7. PubMed PMID: 12012451.

275: Tassone P, Tagliaferri P, Galea E, Palmieri C, Bonelli P, Martelli ML, Tuccillo F, Turco MC, Venuta S. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. Eur J Cancer.

2002 May;38(8):1141-7. PubMed PMID: 12008204.

276: Georgoulias V. Docetaxel (taxotere) in the treatment of non-small cell lung

cancer. Curr Med Chem. 2002 Apr;9(8):869-77. PubMed PMID: 11966449.

277: Giacchetti S. Chronotherapy of colorectal cancer. Chronobiol Int. 2002 Jan;19(1):207-19. PubMed PMID: 11962676.

278: Ferlini C, Distefano M, Pierelli L, Bonanno G, Fattorossi A, Battaglia A, Mancuso S, Scambia G. A new method to evaluate in vitro myelotoxicity of antitumour agents in the first steps of drug development. Pharmacol Toxicol. 2001 Nov;89(5):231-6. PubMed PMID: 11881976.

279: Nilsson EE, Westfall SD, McDonald C, Lison T, Sadler-Riggleman I, Skinner MK. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics. Cancer Chemother Pharmacol. 2002 Feb;49(2):93-100. Epub 2001 Nov 23. PubMed PMID: 11862422.

280: Webster LK, Ellis AG, Apicella C, Deacon GB. Atypical pharmacokinetics and excretion of new platinum analogues in rodents. Cancer Chemother Pharmacol. 2002

Jan;49(1):87-92. PubMed PMID: 11855757.

281: Schenk PW, Boersma AW, Brok M, Burger H, Stoter G, Nooter K. Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype. Mol Pharmacol. 2002 Mar;61(3):659-66. PubMed PMID: 11854447.

282: Oka M, Fukuda M, Nagashima S, Fukuda M, Kinoshita A, Soda H, Doi S, Narasaki F, Suenaga M, Takatani H, Nakamura Y, Kawabata S, Tsurutani J, Kanda T, Kohno S.

Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2001 Dec;48(6):446-50. PubMed PMID: 11800024.

283: Boyle FM, Beatson C, Monk R, Grant SL, Kurek JB. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour

activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol. 2001 Dec;48(6):429-34. PubMed PMID: 11800022.

284: Baumhäkel M, Kasel D, Rao-Schymanski RA, Böcker R, Beckurts KT, Zaigler M, Barthold D, Fuhr U. Screening for inhibitory effects of antineoplastic agents on

CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28. PubMed PMID: 11770832.

285: Morris RE, Aird RE, Murdoch Pdel S, Chen H, Cummings J, Hughes ND, Parsons S, Parkin A, Boyd G, Jodrell DI, Sadler PJ. Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem. 2001 Oct 25;44(22):3616-21. PubMed PMID: 11606126.

286: Inoue A, Saijo N. Recent advances in the chemotherapy of non-small cell lung cancer. Jpn J Clin Oncol. 2001 Jul;31(7):299-304. Review. PubMed PMID: 11518741.

287: Waszkiewicz K. [About side effects of platinum drugs]. Postepy Hig Med Dosw. 2001;55(3):387-406. Review. Polish. PubMed PMID: 11505639.

288: Shih C, Teicher BA. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Des. 2001 Sep;7(13):1259-76. Review. PubMed PMID: 11472266.

289: Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics

and drug dosing. Invest New Drugs. 2001 May;19(2):171-7. Review. PubMed PMID: 11392451.

290: McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol. 2001 Jul 15;62(2):207-12. PubMed PMID: 11389879.

291: Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin

on neuronal voltage-gated sodium channels. J Neurophysiol. 2001 May;85(5):2293-7. PubMed PMID: 11353042.

292: Alberts DS, Hallum AV 3rd, Stratton-Custis M, Garcia DJ, Gleason-Guzman M, Salmon SE, Santabarbara P, Niesor EJ, Floret S, Bentzen CL. Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res. 2001 May;7(5):1246-50. PubMed PMID: 11350890.

293: Yasuda M, Kimura E, Ochiai K, Tada S, Udagawa Y, Aoki D, Nozawa S, Kikuchi Y, Kita T, Nishida M, Tsunoda H. [Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)]. Gan To Kagaku Ryoho. 2001 Apr;28(4):493-8. Japanese. PubMed PMID: 11329783.

294: Borrmann L, Kim I, Schultheiss D, Rogalla P, Bullerdiek J. Regulation of the expression of HMG1, a co-activator of the estrogen receptor. Anticancer Res. 2001 Jan-Feb;21(1A):301-5. PubMed PMID: 11299752.

295: Vermorken JB. The role of intraperitoneal chemotherapy in epithelial ovarian cancer. Int J Gynecol Cancer. 2000 Jan;10(S1):26-32. PubMed PMID: 11240729.

296: Kreis W, Budman DR, Calabro A. A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemother Pharmacol. 2001;47(1):78-82. PubMed PMID: 11221966.

297: Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. Review. PubMed PMID: 11219485.

298: Mese H, Ueyama Y, Suzuki A, Nakayama S, Sasaki A, Hamakawa H, Matsumura T. Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line. Chemotherapy. 2001 Mar-Apr;47(2):136-42. PubMed PMID: 11173816.

299: Fujiwara K, Maehata K, Kohno I, Yoden E, Imajo Y, Mikami Y. [A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy]. Gan To Kagaku Ryoho. 2000 Dec;27(14):2259-62. Japanese. PubMed PMID: 11142173.

300: Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B, Miki T. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol. 2001 Jan;165(1):263-70. PubMed PMID: 11125422.

301: Husain K, Scott RB, Whitworth C, Somani SM, Rybak LP. Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system. Hear Res. 2001 Jan;151(1-2):71-78. PubMed PMID: 11124453.

302: van den Bongard HJ, Mathôt RA, Beijnen JH, Schellens JH. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet. 2000 Nov;39(5):345-67. Review. PubMed PMID: 11108434.

303: Tate S, Iwasaki H, Matsui H, Hirai Y, Sekiya S. [Evaluation of adverse effects including neurotoxicity of combination chemotherapy with paclitaxel and carboplatin]. Gan To Kagaku Ryoho. 2000 Nov;27(13):2087-95. Japanese. PubMed PMID: 11103240.

304: Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000 Nov 1;60(21):6039-44.

PubMed PMID: 11085525.

305: Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs. 2000 Jun;9(6):1373-82. Review. PubMed PMID: 11060749.

306: Jones DV Jr, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, Hellmann S, Fyfe G. Recombinant human thrombopoietin clinical development. Stem Cells. 1998;16 Suppl 2:199-206. PubMed PMID: 11012192.

307: Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol. 2000 Aug;35(2):75-93. Review. PubMed PMID: 10936465.

308: Nakamura M, Abe Y, Katoh Y, Oshika Y, Hatanaka H, Tsuchida T, Yamazaki H, Kijima H, Inoue H, Ueyama Y. A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration. Anticancer Res. 2000 May-Jun;20(3B):1921-5. PubMed PMID: 10928127.

309: van Maanen MJ, Huitema AD, Beijen JH. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate. Anticancer Res.

2000 May-Jun;20(3A):1711-6. PubMed PMID: 10928097.

310: Maanen MJ, Smeets CJ, Beijnen JH. Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev. 2000 Aug;26(4):257-68. Review. PubMed PMID: 10913381.

311: Gross M, Hiesse C, Kriaa F, Goldwasser F. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. Anticancer Drugs. 1999 Jul;10(6):533-6. PubMed PMID: 10885900.

312: Yu DS, Sun GH, Ma CP, Chang SY. Verapamil modulation of multidrug resistance in renal cell carcinoma. J Formos Med Assoc. 2000 Apr;99(4):311-6. Erratum in: J

Formos Med Assoc 2000 Sep;99(9):740. PubMed PMID: 10870315.

313: O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs. 2000;59 Suppl 4:19-27. Review. PubMed PMID: 10864227.

314: Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity

of anticancer agents mediated by electroporation in vitro. Anticancer Drugs. 2000 Mar;11(3):201-8. PubMed PMID: 10831279.

315: Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000 May;6(5):2053-63. PubMed PMID: 10815932.

316: He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and

sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U

S A. 2000 May 23;97(11):5768-72. PubMed PMID: 10811891; PubMed Central PMCID: PMC18508.

317: Rousseau A, Marquet P, Debord J, Sabot C, Lachâtre G. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet.

2000 Apr;38(4):315-53. Review. PubMed PMID: 10803455.

318: Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res. 2000 Apr;6(4):1314-21. PubMed PMID: 10778956.

319: Muramatsu Y, Hasegawa Y, Fukano H, Ogawa T, Namuba M, Mouri K, Fujimoto Y, Matsuura H, Takai Y, Mori M. Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses. Anticancer Res. 2000 Jan-Feb;20(1A):257-64. PubMed PMID: 10769664.

320: Bakhshandeh A, Bruns I, Eberhardt K, Wiedemann GJ. [Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma]. Dtsch Med Wochenschr. 2000 Mar 17;125(11):317-9. Review. German. PubMed PMID: 10761473.

321: Horikoshi T, Naganuma H, Ohashi Y, Ueno T, Nukui H. Enhancing effect of electric stimulation on cytotoxicity of anticancer agents against rat and human glioma cells. Brain Res Bull. 2000 Mar 15;51(5):371-8. PubMed PMID: 10715556.

322: Dowell JA, Sancho AR, Anand D, Wolf W. Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors. Adv Drug Deliv Rev. 2000 Mar 15;41(1):111-26. Review. PubMed PMID: 10699308.

323: Hirano Y, Ushiyama T, Suzuki K, Fujita K. Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological

cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res. 1999 Dec;27(6):483-8. PubMed PMID: 10651138.

324: Vogt A, Wang AS, Johnson CS, Fabisiak JP, Wipf P, Lazo JS. In vivo antitumor activity and induction of insulin-like growth factor-1-resistant apoptosis by SC-alphaalphadelta9. J Pharmacol Exp Ther. 2000 Feb;292(2):530-7. PubMed PMID: 10640289.

325: Nakagawa S, Miki T, Akaza H, Ozono S, Okano T, Sonoda Y, Tsukamoto T, Terachi T, Naito K, Naito S, Nishiyama T, Nonomura N, Hara I, Hoshi S, Yoshida O. [High-dose chemotherapy with peripheral blood stem cell autotransplantation for patients with poor-risk testicular germ cell tumors--pilot study of the Japan Blood Cell Transplantation Study Group]. Hinyokika Kiyo. 1999 Nov;45(11):805-9. Japanese. PubMed PMID: 10637748.

326: Kelland LR. Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. J Inorg Biochem. 1999

Oct;77(1-2):121-4. PubMed PMID: 10626364.

327: Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J Inorg Biochem. 1999 Oct;77(1-2):111-5. Review. PubMed PMID: 10626362.

328: Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf. 1999 Nov;21(5):367-87. Review. PubMed PMID: 10554052.

329: Wouters BG, Wang LH, Brown JM. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol. 1999;10 Suppl 5:S29-33. PubMed PMID: 10582136.

330: Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small

cell lung cancer. Oncologist. 1999;4(5):408-16. PubMed PMID: 10551557.

331: Bloemink MJ, Pérez JM, Heetebrij RJ, Reedijk J. The new anticancer drug [(2R)-aminomethylpyrrolidine](1, 1-cyclobutanedicarboxylato)platinum(II) and its

toxic S enantiomer do interact differently with nucleic acids. J Biol Inorg Chem. 1999 Oct;4(5):554-67. PubMed PMID: 10550684.

332: Mizushima Y, Sassa K, Fujishita T, Oosaki R, Kobayashi M. Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at different sites in rats. J Immunother. 1999 Sep;22(5):401-6. PubMed PMID: 10546155.

333: Desrame J, Broustet H, Darodes de Tailly P, Girard D, Saissy JM. Oxaliplatin-induced haemolytic anaemia. Lancet. 1999 Oct 2;354(9185):1179-80. PubMed PMID: 10513718.

334: Teuben JM, Bauer C, Wang AH, Reedijk J. Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major

adduct in cells treated with the anticancer drug carboplatin. Biochemistry. 1999

Sep 21;38(38):12305-12. PubMed PMID: 10493798.

335: Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson

W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A. Paclitaxel chemotherapy after autologous

stem-cell transplantation and engraftment of hematopoietic cells transduced with

a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res. 1999 Jul;5(7):1619-28. PubMed PMID: 10430060.

336: Sandman KE, Marla SS, Zlokarnik G, Lippard SJ. Rapid fluorescence-based reporter-gene assays to evaluate the cytotoxicity and antitumor drug potential of platinum complexes. Chem Biol. 1999 Aug;6(8):541-51. PubMed PMID: 10421759.

337: Wang XY, Liu HT. Antisense expression of protein kinase C alpha improved sensitivity to anticancer drugs in human lung cancer LTEPa-2 cells. Zhongguo Yao

Li Xue Bao. 1998 May;19(3):265-8. PubMed PMID: 10375741.

338: Yamada M, Tomida A, Yun J, Cai B, Yoshikawa H, Taketani Y, Tsuruo T. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother Pharmacol. 1999;44(1):59-64. PubMed PMID: 10367750.

339: Luo FR, Wyrick SD, Chaney SG. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol. 1999;44(1):29-38. PubMed PMID: 10367746.

340: Schlemmer HP, Becker M, Bachert P, Dietz A, Rudat V, Vanselow B, Wollensack

P, Zuna I, Knopp MV, Weidauer H, Wannenmacher M, van Kaick G. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. 1999 May 15;59(10):2363-9. PubMed PMID: 10344745.

341: Morikawa N, Mori T, Abe T, Kawashima H, Takeyama M, Hori S. Pharmacokinetics of etoposide and carboplatin in cerebrospinal fluid and plasma during hyperosmotic disruption of the blood brain barrier and intraarterial combination

chemotherapy. Biol Pharm Bull. 1999 Apr;22(4):428-31. PubMed PMID: 10328568.

342: Kanzawa F, Nishio K, Fukuoka K, Sunami T, Saijo N. In vitro interactions of

a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model. Cancer Chemother Pharmacol. 1999;43(5):353-63. PubMed PMID: 10100589.

343: Takayama K, Nakanishi Y, Takano K, Harada T, Inoue K, Osaki S, Minami T, Hara N. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity]. Gan To Kagaku Ryoho. 1999 Mar;26(4):503-8. Japanese. PubMed PMID: 10097747.

344: Maeda Y, Matsumoto K, Mizumatsu S, Tamiya T, Furuta T, Ohmoto T. Effect of intracarotid infusion of etoposide: modification of the permeability of the blood-brain barrier and the blood-tumor barrier in rat brain tumor model. Acta Med Okayama. 1999 Feb;53(1):5-11. PubMed PMID: 10096732.

345: Yamada K, Sato T, Yamada A, Tanaka S, Fujii S, Matuo R, Murata K, Manabe T,

Oda J. [A case of hepatocellular carcinoma with tumor thrombus in the right atrium successfully treated by arterial administration of lipiodol-SMANCS]. Gan To Kagaku Ryoho. 1999 Feb;26(3):361-4. Japanese. PubMed PMID: 10065101.

346: Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. [Clinical activity spectrum of irinotecan]. Bull Cancer. 1998 Dec;Spec No:21-5. Review. French. PubMed PMID: 9932080.

347: Chvetzoff G, Bonnotte B, Chauffert B. [Anticancer chemotherapy. Prevention of toxicity]. Presse Med. 1998 Dec 12;27(39):2106-12. Review. French. PubMed PMID: 9893704.

348: Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998 Sep;34(10):1535-42. Review. PubMed PMID: 9893624.

349: Durant ST, Morris MM, Illand M, McKay HJ, McCormick C, Hirst GL, Borts RH, Brown R. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by

inactivation of mismatch repair genes. Curr Biol. 1999 Jan 14;9(1):51-4. PubMed PMID: 9889125.

350: Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs. 1998 Dec;56(6):1019-38. Review.

PubMed PMID: 9878990.

351: Tohnai I, Fuwa N, Hayashi Y, Kaneko R, Tomaru Y, Hibino Y, Ueda M. New superselective intra-arterial infusion via superficial temporal artery for cancer of the tongue and tumour tissue platinum concentration after carboplatin (CBDCA)

infusion. Oral Oncol. 1998 Sep;34(5):387-90. PubMed PMID: 9861346.

352: Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer. 1998 Jul;34(8):1250-9. PubMed PMID: 9849488.

353: Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. Review. PubMed PMID: 9834817.

354: Harrison RV. An animal model of auditory neuropathy. Ear Hear. 1998 Oct;19(5):355-61. PubMed PMID: 9796644.

355: Mese H, Sasaki A, Alcalde RE, Nakayama S, Matsumura T. Establishment and characterization of cisplatin-resistant human epidermoid carcinoma cell line, A431 cell. Chemotherapy. 1998 Nov-Dec;44(6):414-20. PubMed PMID: 9755302.

356: Brown JM, Wang LH. Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des. 1998 Sep;13(6):529-39. Review. PubMed PMID: 9755717.

357: Shi Y, Inoue S, Shinozaki R, Fukue K, Kougo T. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro.

Jpn J Cancer Res. 1998 Jul;89(7):757-67. PubMed PMID: 9738983.

358: Gasperi-Campani A, Roncuzzi L, Zoli W, Lenzi L, Gruppioni R, Sensi A, Zini N, Farabegoli F, Amadori D. Chromosomal alterations, biological features and in vitro chemosensitivity of SCLC-R1, a new cell line from human metastatic small cell lung carcinoma. Eur J Cancer. 1998 Apr;34(5):724-30. PubMed PMID: 9713281.

359: Takeno S, Wake M, Mount RJ, Harrison RV. Degeneration of spiral ganglion cells in the chinchilla after inner hair cell loss induced by carboplatin. Audiol Neurootol. 1998 Sep-Oct;3(5):281-90. PubMed PMID: 9705525.

360: Kurbacher CM, Mallmann PK. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Res. 1998 May-Jun;18(3C):2203-10. Review. PubMed PMID: 9703784.

361: Mizutani Y, Yoshida O, Bonavida B. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). J Urol.

1998 Aug;160(2):561-70. PubMed PMID: 9679929.

362: Nanda GS, Sun FX, Hofmann GA, Hoffman RM, Dev SB. Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in

animal model. Anticancer Res. 1998 May-Jun;18(3A):1361-6. PubMed PMID: 9673341.

363: McFadden SL, Kasper C, Ostrowski J, Ding D, Salvi RJ. Effects of inner hair

cell loss on inferior colliculus evoked potential thresholds, amplitudes and forward masking functions in chinchillas. Hear Res. 1998 Jun;120(1-2):121-32. PubMed PMID: 9667436.

364: Becker M, Port RE, Zabel HJ, Zeller WJ, Bachert P. Monitoring local disposition kinetics of carboplatin in vivo after subcutaneous injection in rats

by means of 195Pt NMR. J Magn Reson. 1998 Jul;133(1):115-22. PubMed PMID: 9654475.

365: Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol. 1998 Mar;9(3):255-60. PubMed PMID: 9602258.

366: Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res. 1998 Apr;4(4):1021-9. PubMed PMID: 9563898.

367: Ohmori T, Arteaga CL. Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP): potential role in CDDP-mediated cytotoxicity. Cell Growth Differ. 1998 Apr;9(4):345-53. PubMed PMID: 9563854.

368: Mizushima Y, Li H, Sassa K, Fujishita T, Oosaki R, Kobayashi M. Grouping of

anticancer drugs based on administration method-related toxicity patterns in rats. Anticancer Res. 1997 Nov-Dec;17(6D):4611-4. PubMed PMID: 9494577.

369: Fujii T, Nakata N, Shiroyama Y, Sawasaki T, Tanimoto H, Shigemasa K, Kioka H, Naito H. [Multi-drug antiemetic treatment and effect of treatment duration of

concurrent steroids--for complete control of chemotherapy-induced nausea/vomiting in gynecological cancer]. Gan To Kagaku Ryoho. 1997 Dec;24(15):2245-52. Japanese. PubMed PMID: 9422069.

370: Chen W, He J, Olson JJ, Lu DR. Direct intracerebral delivery of carboplatin

from PLGA microspheres against experimental malignant glioma in rats. Drug Deliv. 1998;5(2):101-10. PubMed PMID: 19570001.

371: Kawabata K, Nio Y, Imamura M. 5-Fluorouracil + cisplatin + mitomycin C is a

relatively most effective combination against xenograft lines of human colorectal cancer. Anticancer Drugs. 1997 Sep;8(8):790-6. PubMed PMID: 9396624.

372: el-Yazigi A, Ezzat A. Pharmacokinetic monitoring of anticancer drugs at King Faisal Specialist Hospital, Riyadh, Saudi Arabia. Ther Drug Monit. 1997 Aug;19(4):390-3. PubMed PMID: 9263378.

373: Wang J, Chen J, Ma S. [Preoperative intraperitoneal versus intravenous carboplatin chemotherapy for advanced gastric cancer, pharmacokinetics and drug accumulation study]. Zhonghua Zhong Liu Za Zhi. 1997 Jul;19(4):300-2. Chinese. PubMed PMID: 11038765.

374: Baxevanis CN, Tsavaris NB, Papadhimitriou SI, Zarkadis IK, Papadopoulos NG,

Bastounis EA, Papamichail M. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer. 1997 Jul;33(8):1202-8. PubMed PMID: 9301443.

375: van Warmerdam LJ. Tailor-made chemotherapy for cancer patients. Neth J Med.

1997 Jul;51(1):30-5. Review. PubMed PMID: 9260487.

376: Hahn KA, Fields A, Hultgren JL, Nolan ML, Legendre AM. Dose response and time course of carboplatin-induced micronucleated polychromatic erythrocytes in the cat: implications for combination carboplatin chemotherapy. Chemotherapy. 1997 Jul-Aug;43(4):282-7. PubMed PMID: 9209785.

377: Douchi T, Kosha S, Kan R, Nakamura S, Oki T, Nagata Y. Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents. Obstet Gynecol. 1997 Jul;90(1):12-5. PubMed PMID: 9207804.

378: Ishihama H, Nagai S, Umezu H, Ikeda Y, Sugita K, Kobayashi S, Chimoto M, Shimada K. [The usefulness of fibrin glue spraying combined with CDDP for lung cancer]. Gan To Kagaku Ryoho. 1997 Jun;24(8):981-5. Japanese. PubMed PMID: 9212808.

379: Maestroni GJ, Togni M, Covacci V. Norepinephrine protects mice from acute lethal doses of carboplatin. Exp Hematol. 1997 Jun;25(6):491-4. PubMed PMID: 9197326.

380: Chi KH, Chang YC, Chan WK, Liu JM, Law CK, Lo SS, Shu CH, Yen SH, Whang-Peng J, Chen KY. A phase II study of carboplatin in nasopharyngeal carcinoma. Oncology. 1997 May-Jun;54(3):203-7. PubMed PMID: 9143400.

381: Sharma P, Bach PH. Inhibitory effects of platinum anticancer agents on rat brain protein kinase C. Biochem Soc Trans. 1997 Feb;25(1):73S. PubMed PMID: 9056971.

382: Jirsová K, Mandys V. Differences in the inhibition of neuritic outgrowth in

organotypic cultures of rat foetal dorsal root ganglia treated with cisplatin and carboplatin: a comparative study. Folia Histochem Cytobiol. 1997;35(4):215-9. PubMed PMID: 9619421.

383: Miki T, Sawada M, Nonomura N, Kojima Y, Okuyama A, Maeda O, Saiki S, Kotake

T. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice. Eur Urol. 1997;31(1):92-6. PubMed PMID: 9032542.

384: Yamashita F, Tanaka M, Andou E, Yutani S, Kato O, Tanikawa K. Carboplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Oncology. 1997 Jan-Feb;54(1):28-33. PubMed PMID: 8978589.

385: Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996 Dec 24;52(12):1855-65. PubMed PMID: 8951344.

386: Marani TM, Trich MB, Armstrong KS, Ness PM, Smith J, Minniti C, Sandler SG.

Carboplatin-induced immune hemolytic anemia. Transfusion. 1996 Nov-Dec;36(11-12):1016-8. PubMed PMID: 8937414.

387: Takeda S, Ikeba K, Ohokubo T, Sodemoto T, Yamamoto T, Takagi A, Hayashi N, Kinoshita K. [Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy]. Gan To Kagaku Ryoho. 1996 Oct;23(12):1697-703. Japanese. PubMed PMID: 8886048.

388: Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer. 1996 Sep;4(5):341-50. Review. PubMed PMID: 8883227.

389: Fujimura T, Yonemura Y, Minami M, Sato T, Kawamura T, Nojima N, Kinami S, Hirono Y, Fushida S, Nishimura G, Noguchi M, Miwa K, Miyazaki I, Shiobara S. [Chemohyperthermic peritoneal perfusion and high-dose chemotherapy followed by peripheral blood stem cell transplantation in advanced colon cancer--a case report]. Gan To Kagaku Ryoho. 1996 Sep;23(11):1578-80. Japanese. PubMed PMID: 8854810.

390: Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res. 1996 Aug 17;355(1-2):59-70. Review. PubMed PMID: 8781577.

391: Jeremić B, Sibamoto J, Abe M. [Significance of formation of micronuclei in SCC VII murine cells treated with various chemotherapeutic agents]. Srp Arh Celok Lek. 1996 Jul-Aug;124(7-8):169-74. Serbian. PubMed PMID: 9102841.

392: Jeremic B, Shibamoto Y, Abe M. Assessment of micronucleus induction in murine SCCVII cells treated with various anticancer agents. Chemotherapy. 1996 Jul-Aug;42(4):266-72. PubMed PMID: 8804794.

393: Natoli C, Salini V, Irtelli L, Martino MT, Garufi C, Grassadonia A, Fiorentino B, Iacobelli S. A phase I study of 5-day continuous venous infusion of carboplatin at circadian rhythm-modulated rate compared with constant rate. Anticancer Res. 1996 May-Jun;16(3A):1275-9. PubMed PMID: 8702250.

394: Overbeck TL, Knight JM, Beck DJ. A comparison of the genotoxic effects of carboplatin and cisplatin in Escherichia coli. Mutat Res. 1996 Apr 2;362(3):249-59. PubMed PMID: 8637503.

395: Barnham KJ, Djuran MI, Murdoch PS, Ranford JD, Sadler PJ. Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids. Inorg Chem. 1996 Feb 14;35(4):1065-1072. PubMed PMID: 11666286.

396: Xu W, Liang M. [Chemosensitivity test for head and neck cancers]. Zhonghua Er Bi Yan Hou Ke Za Zhi. 1996;31(4):210-3. Chinese. PubMed PMID: 9642344.

397: Jirsová K, Mandys V. Carboplatin-induced micronuclei formation in non-neuronal cells of rat foetal dorsal root ganglia cultured in vitro and comparison with another anticancer drug--cisplatin. Sb Lek. 1996;97(3):331-42. PubMed PMID: 9174376.

398: Kasabdji D, Shanmugam V, Rathinavelu A. Effect of cisplatin on dopamine release from PC12 cells. Life Sci. 1996;59(21):1793-801. PubMed PMID: 8937506.

399: Liu WP, Que ZH, Yang YK, Xiong HZ. [The photolytical products of aqueous carboplatin solution]. Yao Xue Xue Bao. 1996;31(1):72-4. Chinese. PubMed PMID: 8762463.

400: Bloemink MJ, Reedijk J. Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met Ions Biol Syst. 1996;32:641-85. Review. PubMed PMID: 8640534.

401: Kitada M, Sawaragi I. [Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors]. Gan To Kagaku Ryoho. 1996 Jan;23(1):87-91. Japanese. PubMed PMID: 8546476.

402: Nakanishi Y. [Introduction and prospect of peripheral blood stem cell transplantation]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Dec;33 Suppl:24-8. Japanese. PubMed PMID: 8752478.

403: Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, Boracchi P, Guglielmi RB, Pezzella F. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res. 1995 Nov;1(11):1375-83.

PubMed PMID: 9815934.

404: Maestroni GJ. Adrenergic regulation of haematopoiesis. Pharmacol Res. 1995 Nov;32(5):249-53. Review. PubMed PMID: 8868054.

405: Yano K, Matsuoka H, Seo Y, Kounoe S, Saito T, Tomoda H. Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer. Anticancer Res. 1995 Nov-Dec;15(6B):2883-7. PubMed PMID: 8669883.

406: van Warmerdam LJ, van Tellingen O, ten Bokkel Huinink WW, Rodenhuis S, Maes

RA, Bijnen JH. Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements? Ther Drug Monit. 1995 Oct;17(5):465-70. PubMed PMID: 8585109.

407: Ferguson PJ. Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. J Otolaryngol. 1995 Aug;24(4):242-52. Review. PubMed PMID: 8551538.

408: Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, den Engelse L, Baan RA, Berends F, Fichtinger-Schepman AM. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry. 1995 Jul 4;34(26):8474-80. PubMed PMID: 7599137.

409: Kusumoto T, Holden SA, Ara G, Teicher BA. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia. 1995 Jul-Aug;11(4):575-86. PubMed PMID: 7594810.

410: Cserháti T. Charge-transfer chromatographic study of the complex formation of some anticancer drugs with gamma-cyclodextrin. Anal Biochem. 1995 Mar 1;225(2):328-32. PubMed PMID: 7762799.

411: Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized

study. Anticancer Res. 1995 Mar-Apr;15(2):543-50. PubMed PMID: 7539237.

412: Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995 Feb 1;55(3):590-6. PubMed PMID: 7834629.

413: Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing

guidelines for altered renal function. Cancer Treat Rev. 1995 Jan;21(1):33-64. Review. PubMed PMID: 7859226.

414: Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, Kim KH, Hong WS. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother Pharmacol. 1995;35(5):441-5. PubMed PMID: 7850928.

415: Misawa T, Kikkawa F, Maeda O, Obata NH, Higashide K, Suganuma N, Tomoda Y. Establishment and characterization of acquired resistance to platinum anticancer

drugs in human ovarian carcinoma cells. Jpn J Cancer Res. 1995 Jan;86(1):88-94. PubMed PMID: 7737915.

416: Matsuoka H, Eura M, Chikamatsu K, Nakano K, Kanzaki Y, Masuyama K, Ishikawa

T. Low doses of anticancer drugs increase susceptibility of tumor cells to lysis

by autologous killer cells. Anticancer Res. 1995 Jan-Feb;15(1):87-92. PubMed PMID: 7733647.

417: Hong WS, Kim HT, Kim KH, Kim DK. In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines. Anticancer Res. 1995 Jan-Feb;15(1):51-4. PubMed PMID: 7733640.

418: Kim DK, Kim HT, Tai JH, Cho YB, Kim TS, Kim KH, Park JG, Hong WS. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother Pharmacol. 1995;37(1-2):1-6. PubMed PMID: 7497577.

419: Palma JP, Aggarwal SK. Cisplatin and carboplatin mediated release of cytolytic factors in murine peritoneal macrophages in vitro. Anticancer Drugs. 1994 Dec;5(6):615-22. PubMed PMID: 7888698.

420: Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer. 1994 Nov 1;74(9):2546-54. PubMed PMID: 7923012.

421: Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Drugs. 1994 Nov;48(5):794-847. Review. PubMed PMID: 7530632.

422: Comis RL. Cisplatin: the future. Semin Oncol. 1994 Oct;21(5 Suppl 12):109-13. Review. PubMed PMID: 7992062.

423: Suzuki K, Orikasa S, Hoshi S, Yoshikawa K, Saitoh S, Ohyama C, Satoh M, Kawamura S. [Combination therapy of high energy under water shock waves and anticancer drugs for subcutaneous murine bladder cancer (MBT-2)]. Nippon Hinyokika Gakkai Zasshi. 1994 Oct;85(10):1464-73. Japanese. PubMed PMID: 7990295.

424: Szelenyi I, Herold H, Göthert M. Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents. J Pharmacol Toxicol Methods. 1994

Oct;32(2):109-16. PubMed PMID: 7865862.

425: Courjault-Gautier F, Hoet D, Leroy D, Toutain HJ. Dissimilar alterations of

sodium-coupled uptake by platinum-coordination complexes in renal proximal tubular cells in primary culture. J Pharmacol Exp Ther. 1994 Sep;270(3):1097-104. PubMed PMID: 7932157.

426: Elliott WL, Roberts BJ, Howard CT, Leopold WR 3rd. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Cancer Res. 1994 Aug 15;54(16):4412-8. PubMed PMID: 8044790.

427: Akutsu M, Suzuki K, Tsunoda S, Kano Y, Miura Y. [Effects of SN-38 in combination with other anticancer agents against Dauji cells]. Gan To Kagaku Ryoho. 1994 Aug;21(10):1607-11. Japanese. PubMed PMID: 8060135.

428: Amorusi P, Lessard D, Bansal SK, Selinger K, Yacobi A, Tonelli AP. Analysis

of enloplatin by liquid chromatography and of platinum by atomic absorption spectrometry in various biological fluids. J Pharm Biomed Anal. 1994 Aug;12(8):1023-33. PubMed PMID: 7819376.

429: Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA.

Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther. 1994 Apr;19(2):127-33. PubMed PMID: 8071393.

430: Ogawa M, Ariyoshi Y. New anticancer drugs under clinical trials in Japan. Hematol Oncol Clin North Am. 1994 Apr;8(2):277-87. Review. PubMed PMID: 8040141.

431: Uchibayashi T, Lee SW, Kunimi K, Ohkawa M, Endo Y, Noguchi M, Sasaki T. Studies of effects of anticancer agents in combination with/without hyperthermia

on metastasized human bladder cancer cells in chick embryos using the polymerase

chain reaction technique. Cancer Chemother Pharmacol. 1994;35 Suppl:S84-7. PubMed PMID: 7994794.

432: Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol. 1993 Dec;15(3):191-219. Review. PubMed PMID: 8142057.

433: Uchibayashi T, Lee SW, Hisazumi H, Naito K, Endo Y, Noguchi M, Tanaka M, Sasaki T. [Studies of combined treatment of radiofrequency hyperthermia with anticancer agents or irradiation for invasive bladder cancer]. Hinyokika Kiyo. 1993 Dec;39(12):1209-13. Japanese. PubMed PMID: 7506870.

434: Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin

Chem. 1993 Nov;39(11 Pt 2):2419-30. Review. PubMed PMID: 8222253.

435: Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993 Nov 1;53(21):5225-32. PubMed PMID: 8106143.

436: Tonetti M, Giovine M, Gasparini A, Benatti U, De Flora A. Enhanced formation of reactive species from cis-diammine-(1,1-cyclobutanedicarboxylato)-platinum(II) (carboplatin) in the presence of oxygen free radicals. Biochem Pharmacol. 1993 Oct 19;46(8):1377-83. PubMed PMID: 8240386.

437: Ueda O, Suzuki H, Matsuoka A, Sugiyama O, Adachi J. [An application of in vitro fertilization--embryo culture--embryo transfer system on the drug safety evaluation: fertility test of male mice administered with the anticancer drug]. Jikken Dobutsu. 1993 Oct;42(4):565-70. Japanese. PubMed PMID: 8253134.

438: Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired

resistance to cisplatin. Br J Cancer. 1993 Aug;68(2):240-50. PubMed PMID: 8347478; PubMed Central PMCID: PMC1968570.

439: Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tamakoshi K, Mizuno K, Kawai M, Suganuma N, Tomoda Y. Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells. Anticancer Res. 1993 Jul-Aug;13(4):891-6.

PubMed PMID: 8352556.

440: Fujiwara Y, Nakamura M, Yokoo S. A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells. Br J Cancer. 1993 Jun;67(6):1285-92. PubMed PMID: 8512813; PubMed Central PMCID: PMC1968491.

441: Baiocchi G, Scambia G, Benedetti P, Menichella G, Testa U, Pierelli L, Martucci R, Foddai ML, Bizzi B, Mancuso S, et al. Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery. Cancer Res. 1993 Mar 15;53(6):1297-303. PubMed PMID: 7680283.

442: Une Y, Uchino J, Yasuhara M, Misawa K, Kamiyama T, Shimamura T, Sato N, Nakajima Y, Hata Y. Intra-arterial infusion chemotherapy on unresectable hepatocellular carcinoma under occlusion of hepatic arterial flow. Clin Ther. 1993 Mar-Apr;15(2):347-54. PubMed PMID: 8390917.

443: Kano Y, Akutsu M, Suzuki K, Yoshida M. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk Res. 1993 Feb;17(2):113-9. PubMed PMID: 8429687.

444: Delb W, Feilen S, Koch A, Federspil P. [Comparative studies of the ototoxicity of cisplatin and carboplatin]. Laryngorhinootologie. 1993 Jan;72(1):24-7. German. PubMed PMID: 8439352.

445: Herrstedt J, Hyttel J, Pedersen J. Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3,

histamine H1, muscarine cholinergic and alpha 1-adrenergic receptors. Cancer Chemother Pharmacol. 1993;33(1):53-6. PubMed PMID: 8269589.

446: Waxman DJ, Sundseth SS, Srivastava PK, Lapenson DP. Gene-specific oligonucleotide probes for alpha, mu, pi, and microsomal rat glutathione S-transferases: analysis of liver transferase expression and its modulation by hepatic enzyme inducers and platinum anticancer drugs. Cancer Res. 1992 Oct 15;52(20):5797-802. PubMed PMID: 1394205.

447: Newell DR, Maxwell RJ, Golding BT. In vivo and ex vivo magnetic resonance spectroscopy as applied to pharmacokinetic studies with anticancer agents: a review. NMR Biomed. 1992 Sep-Oct;5(5):273-8. Review. PubMed PMID: 1449968.

448: Shimizu A, Kimura T, Funatsu M, Hada Y, Tamura K, Taguchi A, Miyakawa Z, Notake Y. [Intraperitoneal chemotherapy using CBDCA for malignant gynecological tumors]. Gan To Kagaku Ryoho. 1992 Aug;19(10 Suppl):1738-41. Japanese. PubMed PMID: 1530345.

449: Mizushima Y, Kashii T, Nakagawa K, Monno S, Yano S. Effects of granulocyte colony-stimulating factor, interleukin-1 alpha, and interleukin-6 on prolonged myelosuppression induced by nimustine hydrochloride in rats. J Immunother (1991). 1992 Aug;12(2):98-104. PubMed PMID: 1380297.

450: Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res. 1992

Apr 1;52(7):1710-6. PubMed PMID: 1312897.

451: LeBlanc GA, Sundseth SS, Weber GF, Waxman DJ. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res. 1992 Feb 1;52(3):540-7. PubMed PMID: 1732040.

452: Bullen WW, Andress LD, Chang T, Whitfield LR, Welch ML, Newman RA. A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates. Cancer Chemother Pharmacol. 1992;30(3):193-8. PubMed PMID: 1628368.

453: Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother Pharmacol. 1992;30(1):43-50. PubMed PMID: 1586979.

454: Fournier C, Hecquet B, Bastian G, Khayat D. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin. Cancer Chemother Pharmacol. 1992;29(6):461-6. PubMed PMID: 1568289.

455: Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere

against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol. 1992;30(6):444-50. PubMed PMID: 1356649.

456: East CJ, Borch RF. The importance of schedule on diethyldithiocarbamate modulation of drug-induced myelosuppression. Cancer Chemother Pharmacol. 1992;31(2):123-6. PubMed PMID: 1333368.

457: Gergeĺ D, Misík V, Ondrias K. Effect of cisplatin, carboplatin and stobadine on lipid peroxidation of kidney homogenate and phosphatidylcholine liposomes. Physiol Res. 1992;41(2):129-34. PubMed PMID: 1286076.

458: Ayash L, Korbut T, Herman TS, Teicher BA. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating

agents in MCF-7 or MCF-7/CP cells. Cancer Lett. 1991 Dec 9;61(1):7-14. PubMed PMID: 1764699.

459: Fujita H. [Clinical pharmacology of anticancer agents. (Part 1) Introduction, alkylating agents and platinum compounds]. Gan To Kagaku Ryoho. 1991 Nov;18(14):2481-7. Japanese. PubMed PMID: 1952967.

460: Akamatsu K, Endo K, Matsumoto T, Morikawa K, Koizumi M, Koizumi K, Mitsui H. Toxicological and tumoricidal evaluations of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)platinum( II) monohydrate, in rats. Jpn J Cancer Res. 1991 Jun;82(6):724-31. PubMed PMID: 1906857.

461: Nonclercq D, Toubeau G, Lambricht P, Heuson-Stiennon JA, Laurent G. Redistribution of epidermal growth factor immunoreactivity in renal tissue after

nephrotoxin-induced tubular injury. Nephron. 1991;57(2):210-5. PubMed PMID: 2020350.

462: Brillet G, Deray G, Bunker D, Ben Hmida M, Baumelou A, Jacobs C. [Can cisplatin renal toxicity be prevented?]. Nephrologie. 1991;12(3):143-6. Review. French. PubMed PMID: 1922654.

463: Tilby MJ, Johnson C, Knox RJ, Cordell J, Roberts JJ, Dean CJ. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and

in vivo using a monoclonal antibody. Cancer Res. 1991 Jan 1;51(1):123-9. PubMed PMID: 1703029.

464: Schmalbach TK, Borch RF. Mechanism of diethyldithiocarbamate modulation of murine bone marrow toxicity. Cancer Res. 1990 Oct 1;50(19):6218-21. PubMed PMID:

2169339.

465: Ikushima S, Fujiwara F, Todo S, Imashuku S. Gamma linolenic acid alters the

cytotoxic activity of anticancer drugs on cultured human neuroblastoma cells. Anticancer Res. 1990 Jul-Aug;10(4):1055-9. PubMed PMID: 2166461.

466: Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990 Jun 1;50(11):3339-44. PubMed PMID: 2334928.

467: Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, Frei E 3rd. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990 Mar 23;247(4949 Pt 1):1457-61. PubMed PMID: 2108497.

468: Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H. Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents. Eur J Cancer. 1990;26(8):898-901.

PubMed PMID: 2145935.

469: Harrap KR, Jones M, Siracky J, Pollard LA, Kelland LR. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann Oncol. 1990;1(1):65-76. PubMed PMID: 2078487.

470: Nonclercq D, Toubeau G, Tulkens P, Heuson-Stiennon JA, Laurent G. Renal tissue injury and proliferative response after successive treatments with anticancer platinum derivatives and tobramycin. Virchows Arch B Cell Pathol Incl

Mol Pathol. 1990;59(3):143-58. PubMed PMID: 1980761.

471: Saburi Y, Nakagawa M, Ono M, Sakai M, Muramatsu M, Kohno K, Kuwano M. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res. 1989 Dec 15;49(24 Pt 1):7020-5. PubMed PMID: 2479474.

472: Nonclercq D, Toubeau G, Laurent G, Tulkens PM, Heuson-Stiennon JA. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Exp Mol Pathol. 1989 Oct;51(2):123-40. PubMed PMID: 2680578.

473: Kataoka A, Yokota D, Sugiyama T, Oda T, Nishida T, Yakushiji M. [Effects of

anticancer agents on 7, 12-dimethylbenz (a) anthracene induced rat ovarian cancer cell line (DMBA-OC-1) and human ovarian serous adenocarcinoma cell line (KOC-1S)]. Nippon Sanka Fujinka Gakkai Zasshi. 1989 Oct;41(10):1523-9. Japanese.

PubMed PMID: 2511256.

474: Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527-34. PubMed PMID: 2653399; PubMed Central PMCID: PMC2247140.

475: Hannan MA, al-Dakan AA, Hussain SS, Amer MH. Mutagenicity of cisplatin and carboplatin used alone and in combination with four other anticancer drugs. Toxicology. 1989 Apr;55(1-2):183-91. PubMed PMID: 2652378.

476: Miki T, Kotake T. [Anti-cancer drug sensitivity test against human testicular cancer xenograft--comparison with clinical results of chemotherapy]. Hinyokika Kiyo. 1988 Nov;34(11):1903-9. Japanese. PubMed PMID: 3242364.

477: Boughattas NA, Lévi F, Hecquet B, Lemaigre G, Roulon A, Fournier C, Reinberg A. Circadian time dependence of murine tolerance for carboplatin. Toxicol Appl Pharmacol. 1988 Nov;96(2):233-47. PubMed PMID: 3057682.

478: Horiuchi N, Nakagawa K, Sasaki Y, Minato K, Fujiwara Y, Nezu K, Ohe Y, Saijo N. In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay. Cancer Chemother Pharmacol. 1988;22(3):246-50. PubMed PMID: 2842080.

479: Hussain SS, Amer MH, Hannan MA. Cytotoxicity of cisplatin and carboplatin used alone and in combination with the other anticancer drugs in the mouse embryo C3H10T1/2 cell line. Chemotherapy. 1988;34(6):504-11. PubMed PMID: 2468457.

480: Phelps JS, Gandolfi AJ, Brendel K, Dorr RT. Cisplatin nephrotoxicity: in vitro studies with precision-cut rabbit renal cortical slices. Toxicol Appl Pharmacol. 1987 Sep 30;90(3):501-12. PubMed PMID: 3310337.

481: Cohen JD, Robins HI. Hyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro. Cancer Res. 1987 Aug 15;47(16):4335-7. PubMed PMID: 3300964.

482: Azuma A, Hino M, Hirosawa A, Shimabukuro Z, Aoyama A, Ootsuka M, Matsusaka M, Niitani H. [Analysis of drug sensitivity by successive colony-forming assay].

Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 2):815-20. Japanese. PubMed PMID: 3032106.

483: Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986 Apr;46(4 Pt 2):1972-9. PubMed PMID: 3512077.

484: Schurig JE, Florczyk AP, Bradner WT. The mouse as a model for predicting the myelosuppressive effects of anticancer drugs. Cancer Chemother Pharmacol. 1986;16(3):243-6. PubMed PMID: 3698166.

485: Schurig JE, Schlein A, Florczyk AP, Farwell AR, Bradner WT. Animal models for evaluating the myelosuppressive effects of cancer chemotherapeutic agents. Exp Hematol. 1985;13 Suppl 16:101-5. PubMed PMID: 3987834.